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Abstract 
The experiments were carried out on rat isolated aorta and mesenteric 
arteries, on cultured endothelium and arterial smooth muscle cells to investigate the 
vascular response to three sulfonylurea drugs, e.g. glibenclamide, glipizide and 
tolbutamide using various techniques including force measurement, 
radioimmunoassay, Ca?+ fluorescence measurement and cell proliferation. 
Glibenclamide (0.03-1 ^iM) concentration-dependently inhibited or reversed 
vasorelaxation induced by pinacidil and cromakalim, the K+ channel openers, 
however, this reversal effect was significantly enhanced in endothelium-denuded 
arteries. Glibenclamide at a concentration greater than 1 ^iM inhibited contraction 
induced by phenylephrine (1 ^iM), U46619 (30 nM), PDA (1 ^iM) or 60 mM K+. The 
order of potency for glibenclamide or glipizide to relax arteries contracted by these 
four constrictors are U46619 > phenylephrine > high K+ > PDA. Incubation of 
endothelium-intact arteries with inhibitors of nitric oxide activity such as L-NNA, L-
NAME or methylene blue, significantly reduced glibenclamide-induced 
vasorelaxation, while L-arginine antagonized the effect of L-NAME. Glibenclamide 
(100 ^iM) increased the tissue content of cGMP of endothelium-intact tissues; 
pretreatment of L-NNA (100 ^iM) or removal of endothelium suppressed this effect. 
Glibenclamide (30-100 ^iM) elevated the intracellular Ca^^ levels in rat aortic 
endothelial cells in primary culture and in cultured human umbilical cord vein 
endothelial cells. 
Glibenclamide (3-500 ^iM) reduced 60 mM K+-induced contraction and 
CaCl2 (0.1-5 mM)-induced contraction in 60 mM K+-containing solution. Besides, 
glibenclamide (30 ^iM) or nifedipine (100 nM) reduced 60 mM K+-induced increase 
V 
of intracellular [Ca，+] in cultured aortic smooth muscle cells. Glibenclamide also 
reduced the contractile response to active phorbol ester, PDA (1 p,M) in Ca^^-free 
Krebs solution. 
Glibenclamide inhibited proliferation in both cultured endothelium and 
smooth muscle cell. The inhibitory effcet of glibenclamide (100 ^iM) on endothelial 
cell proliferation was attenuated by methylene blue (3 fiM) or Rp-8-cGMP (1 mM), 
but not by L-NAME (10 ^iM). External Ca:+ also inhibited endothelial cell 
proliferation. Glibenclmaide (30-300 ^iM) inhibited proliferation of aortic smooth 
muscle cells in the absence and presence of phenylephrine or PDA. Nifedipine (0.1-1 
^iM) also inhibited aortic cell proliferation. 
Tolbutamide had an opposite effect to glibenclamide and glipizide. 
Tolbutamide (0.1-5 mM) caused a concentration-dependent contraction in both 
endothelium-intact and -denuded arteries. Removal of extracellular Ca〗+ abolished the 
contractile response to tolbutamide. Pretreatment with nickel (0.3 mM), nifedipine (1 
P-M) or thapsigargin (10 nM), significantly reduced tolbutamide-induced contraction, 
while L-NNA, BQ610, forskolin, sodium nitroprusside, staurosporine or prazosin had 
no effect. In addition, pretreatment with guanethidine (10 p,M) or 6-hydroxydopamine 
(3 |iM) was without effect. In cultured rat aortic smooth muscle cells, tolbutamide (5 
mM) increased intracellular [Ca^^] and nickel (1 mM) inhibited this increase. 
It is concluded that (1) glibenclamide induced both endothelium-dependent 
and -independent relaxation, the former is mainly mediated by endothelial nitric oxide 
and the latter is jointly mediated through inhibition of Ca^^ influx and of protein 
kinase C-dependent mechanism; (2) glibenclamide and glipizide are most effective 
against contraction induced by U46619 than other constrictors; (3) the antiproliferaive 
effect of glibenclamide on endothelial cells may be caused by increased endothelial 
VI 
[Ca2+] and probably also by nitric oxide; (4) tolbutamide-induced contraction is 








在內皮完整的血管上，glibendamide (0.03-1 /zM)以濃度依賴性地抑制 
pinacidil和cromakalim所致的血管舒張。在去除內皮的血管，這作用明顯地增 
加�Glibendamide和glipizide抑制四種刺激物引起的血管張力，效力次序如 







胞，加上 methylene blue (3 fiM)和 Rp-8-cGMP (1 mM)會減低 glibenclamide 的抑 
制作用。而提高細胞外躬離子的濃度亦能阻止內皮細胞的增殖。 
相反，tolbutamide (0.1-5 mM)以濃度依賴性地收縮內皮完整或去除內皮 
的血管，但除去細胞外躬離子，則無此作用。而預處理nickel (0.3 mM)， 
nifedipine (1 fjiM)或 thapsigargin (10 nM)減低 tolbutamide 所致的血管張力。但 L-
NNA，BQ610，forskolin，sodium nitroprusside 或 staurosporine 沒有作用 ° 而預處 
理 prazosin (1 "M)，guanethidine (10 jJtM)或 6-hydroxydopamine (3 " M )也無作 
vm 
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Chapter 1 Introduction 
1.1. Sulfonylureas 
The hypoglycaemic effects of sulfonylurea drugs have been known since 1900; 
acetylsalicylic acid is the oldest synthetic oral hypoglycaemic agent (Balant, 1981). So 
far，more than 10,000 derivatives of sulfonylurea compounds have been synthesized 
and biologically tested for their hypoglycaemic activity in animals, but only a few of 
them have been successfully used in medication. 
From a structure-activity point of view, sulfonylureas are classified into two 
groups: the first and second generation (Balant, 1981; Howes et al., 1996; Kuhlmann 
and Plus, 1996). The first generation of sulfonylureas including carbutamide, 
tolbutamide, chlorpropamide, tolcyclamide, acetohexamide, glibornuride, tolazamide 
and gliclazide, usually have a low potency; the daily dose ranges from 100 mg to 1 g 
except for glibornuride and gliclazide (Balant, 1981; Kuhlmann and Plus, 1996). The 
second generation of sulfonylureas such as glibenclamide, glisentide, glipizide, 
glisolamide, gliquidone and glisoxepide, have a high potency. This group of drugs is 
also called N-d-N hypoglycaemic sulphonylurea (Balant, 1981). The daily dose of 
these drugs is within a lower miligram range (Balant, 1981; Kuhlmann and Plus, 
1996). The pharmacokinetics of sulfonylurea compounds are different among animal 
species. For instance, the rate of absorption of sulfonylureas in liver is different 
among various species. Food and other drugs also affect absorption of sulfonylurea 
drugs. After oral administration, most of sulfonylureas are accumulated first in liver 
and pancreatic islets, and finally excreted in the urine. But, different sulfonylurea 
drugs have different metabolic pattern and metabolic rate. For example, glibenclamide 
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is almost completely metabolized in liver, while approximately 90% glipizide is 
metabolized in liver and 10% is excreted in an unchanged form from the kidneys. On 
the other hand, renal excretion is the predominant route for elimination oftolbutamide 
(Kuhlmann and Plus, 1996). 
In this study, I focused on examining the vascular effects ofthree sulfonylurea 
dmgs: tolbutamide, glibenclamide (glyburide) and glipizide. The chemical structures 
ofthese three drugs are related (Howes et al., 1996; Kuhlmann and Plus, 1996), which 
are shown in Figure 1，and their pharmacological kinetic properties are different 
(Feldman, 1985), which are shown in Table 1. These three hypoglycaemic drugs have 
commonly been used in the treatment of non-insulin-dependent diabetes mellitus 
GSfIDDM, also called type II diabetes) (Report, 1997) for several decades (Balant, 
1981; Feldman, 1985; Kuhlmann and Plus, 1996). These agents display a range of 
potency. Glibenclamide is about 200 times and glipizide is about 100 times more 
potent than tolbutamide (Feldman, 1985). 
1.2. Biological action of sulfonylurea drugs 
Sulfonylureas have different modes of action on living cells. Both pancreatic 
and extrapancreatic effects have been suggested to contribute to the therapeutic 
benefit of sulfonylureas for type II diabetic O^IDDM) patients (Kuhlmann and Plus, 
1996). There exists evidence showing that sulfonylureas may directly stimulate insulin 
secretion in pancreatic P-cells (Coore and Randle, 1964; Yalow et aL, 1960). Indirect 
stimulation of insulin secretion by sulfonylureas from extrapancreatic cells was also 
observed in clinical studies (Gerich, 1989). Sulfonylureas are highly protein bound in 
the plasma, only 6% of tolbutamide and less than 1% ofglibenclamide are present in a 
2 
CH3H:^ ^SO2-NH-CO-NH-C4H9 Tolbutamide 
C1 
<^CO-NH-CH2-CH2-<Q^SO2-NH-CO-NH^ Glibenclamide 
“ O C H 3 
CH3^VcO-NH-CH2-CH2<^^SO2-NH-CO-NH^^ Glipizide 
Figure 1 
Chemical structures of tolbutamide, glibenclamide and glipizide, which are used in 
the present study. 
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Table 1 Sulfonylureas: metabolism, potency and activity 
Sulfonylureas Maximum Rate of . Duration of Percentage Equivalent 
(Available year) Dose hepatic Activity in urine therapeutic 
(mg/day) metabolism (hrs) (%) dose (mg) 
First Tolbutamide 3000 Rapid 6- 8 100 1000 
generation (1956) 
Second Glibenclamide 20 Intermediate 24 50 5 
generation (1969) 
Glipizide 40 Intermediate 12 89 10 
(1973) 
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free form (Panten et al., 1989). Panten et al. (1989) found that the non-protein-bound 
sulfonylureas easily cross capillary walls (perhaps penetrating the blood-brain barrier 
capillaries) because of their high lipid solubility. Hence, the free drug concentration at 
the target cells is similar to its plasma concentration. 
7.2.7. Effects on pancreatic P cells 
Sulfonylureas can directly stimulate insulin release from p cells in the islets 
of Langerhans and this effect does not need the presence of nutrients, such as glucose 
or other secretagogues (Gorus et aL, 1988). Electrophysiological studies demonstrate 
that sulfonylureas depolarise the cell membrane of the pancreatic p cells, and produce 
electrical spike activity (Matthews et aL, 1973). The depolarisation is due to a 
decrease in the K+ permeability resulting from inhibition of an ATP-sensitive K+ 
channel (KAip channel) on the p cell plasma membrane (Henquin, 1980). This 
depolarisation stimulates voltage-dependent Ca】+ influx across the cell membrane 
leading to an increase in the cytosolic Ca〗+ concentration and subsequent stimulation 
of insulin secretion (Henquin, 1987) (Fig. 2). Insulin secretion induced by most 
sulfonylureas is probably mediated through a similar mechanism proposed by Panten 
et al. (1989), who found that the maximum effective concentration of tolbutamide, 
glibenclamide or glipizide caused the same maximum secretory rate of insulin from 
the pancreatic p cells. 
In the plasma membrane of rodent or human pancreatic p cells, an inwardly 
rectifying K+ channel was inhibited when the p cells were exposed to glucose or other 
insulin-releasing fuels (Ashcroft and Rorsman, 1991). This is because of an increase 
of ATP and a decrease of ADP concentration at the cytoplasmic face of the p cell 
5 
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The proposed mechanisms underlying the effects of glucose and sulfonylurea drugs on 
pancreatic p cells. When ATP levels are low within a cell, the transmembrane 
potential is maintained negative and K+ diffuses down its concentration gradient. An 
increase in the plasma glucose concentration will promote glucose transport into the 
cell. Intracellular glucose is then hydrolysed to increase intracellular ATP 
concentration, which subsequently causes inhibition of KAiP channels from the 
cytoplasmic side of the cell membrane. Sulfonylurea hypoglycaemic drugs block the 
KATP channel, then cause depolarisation of the membrane. As a result, voltage-gated 
Ca2+ channels open and the influx of Ca^^  triggers insulin secretion. 
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membrane. This points to an important role of KATP channels in the regulation of 
insulin secretion. 
The activity of KAip channels is controlled by separate binding sites for 
sulfonylurea drugs, nucleotides and adenosine as proposed by Ashcroft and Ashcroft 
(1990) (Fig. 3). The sulfonylurea receptor (SR) is suggested to be a transmembrane 
protein containing separate binding sites for sulfonylurea and diazoxide, the latter is a 
KATP channel activator which binds to another site of a sulfonylurea receptor. The 
channel activation is induced by interaction of adenosine with cardiac or vascular A! 
receptor (AiR) (Kirsch et al., 1990) or by intracellular MgADP, while the channel 
inhibition is induced by intracellular ATP. In the absence of nucleotides, sulfonylureas 
have only a week inhibitory effect on the KAip channel activity. Normal regulation of 
the KATP channel requires phosphorylation of both the channel and sulfonylurea 
receptor by a tightly associated protein kinase (Kuhlmann and Plus, 1996). The 
receptor for sulfonylureas plays an important role in controlling the KAip channel 
activity and thus in insulin release (Schmid-Antomarchi et aL, 1987). However, 
sulfonylureas may not exert a direct effect on the delayed rectifying K+ channels, 
Ca2+-activated K+ channels, Ca〗+ channels or non-selected cation channels in the P 
cells (Ashcroft and Rorsman, 1991). The inhibition of KAiP channels in pancreatic p 
cells by glibenclamide and tolbutamide is the major contributor to their 
hypoglycaemic actions (Ashcroft and Ashcroft, 1990). 
7.2.2. Effects on cardiac myocytes 
Since the KAip channel was first described by Noma (1983) in cardiac 
myocytes, an explosion of investigations has provided valuable insight into 
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Figure 3 
Simplified model for the regulation of a KAip channel by nucleotides, sulfonylurea 
drugs and adenosine. Channel activation (black lines) is induced by interaction of 
adenosine with cardiac and vascular Ai receptor (AiR) through a G-protein (Kirsch et 
al., 1990) or by intracellular MgADP. Channel inhibition (dash lines) is induced by 
internal ATP or sulfonylureas. Normal regulation requires phosphorylation (P) ofboth 
KATP channel and sulfonylurea receptor (SR) by a tightly associated protein kinase. 
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mechanisms underlying the physiological control of the cardiac flmction. Many 
studies have confirmed an important role of KAip channels in mediating hypoxia, 
ischaemia and autoregulation, reactive hyperaemia, responses to an increase in 
myocardial oxygen consumption and, effects of myocardial stunning and 
preconditioning situations on the coronary circulation (Dellsperger, 1996). A cardiac 
KATP channel resembles the channel found in pancreatic p cells with similar 
pharmacological properties (Ashcroft and Ashcroft，1990). When the cytoplasmic 
surface of a cardiac myocyte membrane was exposed to a nucleotide-free solution, 
half-maximal inhibition ofKATP channels was achieved at 0.94 mM tolbutamide or at 
0.5 ^iM glibenclamide (Venkatesh et aL, 1991). These values suggest that the 
sensitivity of cardiac KAip channels to sulfonylurea is low, unless both inhibitory and 
stimulatory nucleotides are present at the internal side of the cell membrane, as 
described for the KAXP channel in the pancreatic P cells. However, KAip channels in 
cardiac myocytes appear to be all closed under normal physiological conditions 
because of high ATP and low ADP concentrations found in the cytosol of cardiac 
myocytes QSioma, 1983). 
Hypoxia or ischaemia lowers the intracellular ATP concentration and rises 
ADP and adenosine concentration, as a result, KAip channels open and outward K+ 
current is activated. In addition, adenosine diffuses out of the cardiac myocytes and 
contributes to further opening of KAip channels via an interaction with A i receptors 
(Howes et al., 1996; Kirsch et al., 1990). As a result, the duration of action potential 
shortens. Cellular K+ loss through KAip channels and extracellular K+ accumulation 
are important causes of induction of cardiac arrhythmias (Howes et al., 1996). On the 
other hand, survival of cardiac myocytes is prolonged by action potential shortening 
because of inhibition of voltage-dependent Ca】+ channels and of reduced Ca〗+ influx, 
9 
cardiac contractility and energy consumption. Therefore, sulfonylurea-induced 
blockade of KAip channels during hypoxia or ischaemia might help to inhibit 
occurrence of cardiac arrhythmias (Howes et aL, 1996). Besides, it was shown that 
glibenclamide at 1 ^iM antagonised the pinacidil-induced shortening of the action 
potential duration in guinea pig ventricular myocytes fNakayama et al,, 1990). 
Glibenclamide was also found to inhibit enhancement of reperfusion arrhythmias 
induced by the KAip channel openers (Howes et al., 1996). Zunkler et al. (1997) 
reported that tolbutamide (1-3 mM) blocked the cromakalim-induced activation of 
KATP channels in human right atrial cardiac myocytes. Tolbutamide did not affect 
single channel conductance, but reduced KAip channel open state probability (Zunkler 
et cd., 1997). Although sulfonylureas may have a beneficial action against 
arrhythmias, they also cause myocardial damage (Gross and Auchampach, 1992), 
since a larger dose of glibenclamide, administrated intravenously, has been reported to 
increase the myocardial infarct size in anaesthetised dogs (Auchampach et cd., 1991; 
Gross and Auchampach, 1992). 
On the other hand, the cardioprotective effect is also maintained by the 
opening of KAip channels during ischaemia or by KAip channel openers (Gross and 
Auchampach, 1992). Therefore, sulfonylurea, such as glibenclamide and tolbutamide, 
prevent myocardial KAip channels from opening in patients undergoing an ischaemic 
event, which may result in worsening of ischaemic injury (Gross and Auchampach, 
1992). In aerobic rat hearts, tolbutamide at 0.6 mM markedly stimulated 
glycogenolysis, glucose uptake and utilization, while it decreased fatty acid 
metabolism (Kramer et al., 1983; Tan et al., 1984). These effects, which are 
independent ofinsulin secretion, are even more pronounced in the diabetic hearts (Tan 
et aL, 1984). 
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7.2.J. Effects on smooth muscle cells 
KATP channels play an important role in mediating vascular blood flow in 
response to various physiological stimuli, such as hypoxia and ischaemia (Dellsperger, 
1996). Thus, the diseased states where abnormalities in the function of KAip channels 
may occur, such as hypertension and diabetes, could have dramatic effects on 
responses of the coronary vascular bed to normal physiological stimuli. There are a 
number of potential mediators that regulate the activity of KAip channels in vascular 
smooth muscle cells. Metabolic products, such as hypoxia, acidosis, adenosine or low 
levels of intracellular ATP, could activate KAip channels. Besides, some endogenous 
vasoactive agents, such as calcitonin gene-related peptide and vasoactive intestinal 
polypeptide (VIP), were found to induce vasodilation through activation of KAip 
channels O^elson et aL, 1990; Standen et al., 1989). Increased levels of protein kinase 
C and pertussis toxin-sensitive G-protein coupling have also been shown to be 
associated with the increased open state probability of KAip channels (Dellsperger, 
1996). Endotoxin shock has been recently reported to mediate a hypotensive response 
via stimulation ofKATP channels (Dellsperger, 1996). 
The characterization of high-affinity binding sites for sulfonylureas in 
membrane preparations from vascular and non-vascular smooth muscle (Kovacs and 
Nelson, 1991) suggestes that these cells contain a typical sulfonylurea receptor in 
relation to regulation of the KAip channel activity. Loffler and Quast (1997) reported 
that there are two classes of [^H]-glibenclamide binding sites with low and high 
affinity sites, on smooth muscle cells prepared from rat aorta. They reported that 
glipizide inhibited the high affinity binding sites and also inhibited the low affmity 
binding sites at very high concentration. The KAip channel openers only inhibited the 
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high affinity binding sites with a potency similar to those obtained with vasorelaxation 
studies (L6ffler and Quast, 1997). In rabbit or rat mesenteric arteries, a KAip channel 
conductance at 0 mV was 135 pS and the concentration of ATP that inhibited this 
channel half-maximally was 53 ^iM measured in an inside-out patch (Standen et aL, 
1989). Glibenclamide at 1 ^iM markedly suppressed the activity of an arterial KAip 
channel which had been activated by cromakalim, a KAip channel opener (Standen et 
aL, 1989). 
In vascular and non-vascular smooth muscle cells, glibenclamide blocks the 
hyperpolarisation and dilation of rabbit mesenteric arteries (Standen et al., 1989) and 
guinea pig trachea 0s[ielsen-Kudsk et aL, 1990) in response to several K+ channel 
openers, such as pinacidil, cromakalim and diazoxide. Single channel studies reveal 
that both glibenclamide and tolbutamide caused a concentration-dependent reduction 
in the outward K+ current which had been activated by pinacidil in rabbit mesenteric 
artery (Quayle et cd., 1995). In 30 mM K+-contracted rabbit coronary arteries, 
sulfonylurea drugs displayed an antagonistic effect on the vasorelaxant response to 
cromakalim fNielsen-Kudsk and Thirstrup，1991). On the other hand, glibenclamide 
significantly inhibited the vasodilation induced by infusion of diazoxide in the 
brachial artery of human forearm, but tolbutamide did not have a significant effect 
(Bijlstra et al., 1996). In isolated guinea pig tracheal smooth muscle, glibenclamide 
was more potent than glipizide in antagonising the relaxant response to cromakalim 
but they produced relaxation of smooth muscle contracted by PGF2a, histamine or 30 
mM K+. However, tolbutamide did not antagonize cromakalim-induced relaxation nor 
produced tracheal relaxation QSlielsen-Kudsk and Thirstrup, 1993). 
Glibenclamide effectively inhibited the levcromakalim-induced relaxation 
under both hypoxic and ischaemic conditions (Husken et al., 1997), but the 
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mechanism of hypoxic vasorelaxation may be different among different vascular beds 
or species (Husken et al., 1997). I f a hypoxic condition persists longer, glibenclamide 
cannot inhibit the opening of KATP channel because there may exist other mechanisms. 
It was observed that tolbutamide reduced hypoxic vasoconstriction in rat pulmonary 
artery while glibenclamide showed no effect (Robertson et al., 1992). 
Furthermore, more evidence has amassed to show that sulfonylureas not only 
are blockers of the KAip channels, but also have an inhibitory influence on the 
prostanoid-induced vasoconstriction. Glibenclamide (3-30 ^iM) was reported to 
competitively antagonise the contractile response to a thromboxane A2 mimetic, 
U46619, but tolbutamide did not have such an effect in isolated dog coronary arteries 
(Cocks et al” 1990). Glibenclamide caused relaxation of prostaglandin F2a-
precontracted rat aorta, canine femoral, mesenteric, renal, coronary, basilar and middle 
cerebral arteries (Zhang et aL, 1991). In rabbit coronary arteries, sulfonylurea drugs 
reversed the contractile response to prostaglandin F2a but with different potency. The 
order ofpotency ( E C 5 0 士 S.E.) was glibenclamide (4.75 士 0.38 ^M) > glipizide ( 2 2 2 土 
83 [iM) = tolbutamide (209 士 19 ^iM) 0^^ielsen-Kudsk and Thirstrup, 1991). However, 
glibenclamide had a lower potency against contraction induced by 30 mM K+ ( E C 5 0 = 
114 士 18 ^iM), glipizide and tolbutamide only slightly relaxed the rabbit coronary 
arteries at very high concentrations Q^ielsen-Kudsk and Thirstrup, 1991). Recently, 
Delay and Van de Voorde (1997) described that contractions of rat aorta induced 
prostaglandins, by serotonin or norepinephrine, but not by high K+ can be inhibited by 
glibenclamide and tolbutamide. Glibenclamide also inhibited the prostanoid-induced 
contraction (by U46619 but not by 120 mM K+) in rat retinal and ciliary arteries 
(Delay and Van de Voorde, 1997). In addition, glibenclamide inhibited the 
vasoconstriction induced by U46619 in human internal mammary arteries and 
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saphenous veins (Stanke et aL, 1998). However, prostanoid-induced contraction 
cannot be inhibited by glibenclamdie in guinea pig thoracic aorta (Delaey and Van de 
Voorde, 1997) and in human subcutaneous small arteries (Delaey and Van de Voorde, 
1997; Husken et al., 1995). In this study, I found that glibenclamide and glipizide 
reversed the contractile response not only to U46619 but also to phenylephrine or to 
high K+ in rat thoracic aorta and mesenteric arteries. These results suggest that 
glibenclamide may not only be a competitive inhibitor at prostaglandin receptors. 
Moreover, glibenclamide significantly decreased the endothelin-1 -induced 
contraction in human internal mammary artery (Stanke et aL, 1998). But it did not 
alter contractions elicited by norepinephrine in human internal mammary artery and by 
5-hydroxytryptamine and endothelin-1 in human saphenous vein (Stanke et cd., 1998). 
In dog coronary artery, glibenclamide (30 ^iM) had no influence on the endothelin-I-
induced contraction (Cocks et al., 1990). Therefore, it is possible that glibenclamide 
has different vasorelaxant properties against the constrictor-induced contraction in 
different vascular beds. 
L2.4. Effects on endothelial cells 
The endothelium plays a central role in maintaining the normal vascular tone 
through liberating many vasoactive mediators, such as nitric oxide, prostacyclin, 
endothelium-derived hyperpolarising factor (EDHF), endothelin-1, angiotensin II and 
thromboxane A2 mimetic (Lyons, 1997). Numerous studies suggest that endothelial 
dysfunction contributes to the development of atherosclerotic disease (Lyons, 1997), 
hypertension and ischaemia (Woodman, 1995). Recently, Katnik and Adams (1997) 
have demonstrated the presence of a KAXP conductance in freshly dissociated 
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endothelial cells from rabbit aorta. It was described that activation of endothelial K_ATP 
channels and subsequent membrane hyperpolarisation may contribute to endothelium-
dependent regulation of vascular smooth muscle tone in response to changes in levels 
of intracellular metabolities in endothelium (Katnik and Adams, 1997). Although 
sulfonylurea-sensitive K_ATP channels have been found in rat endothelial cells from 
aorta and brain microvessels (Janigro et al., 1993; Katnik and Adams, 1997), only 
until recently, has the relaxant action of glibenclamide in rat mesenteric arteries been 
found by us to involve endothelium-derived relaxing factors (Huang and Chan, 1998). 
However, there is no information in literature as to a possible effect of glibenclamide 
on endothelial second messenger signaling pathway. 
1.3. Side effects and toxicity 
Although sulfonylurea drugs are clinically used to treat type II diabetic 
patients, these agents still have some adverse effects. Administration of sulfonylureas 
to various animal species including human would cause acute and chronic toxicity. 
However, different sulfonylureas may have different chronic toxicity. There are some 
data showing that the second generation of sulfonylureas are much more potent and 
less toxic than the first generation of sulfonylureas (Kuhlmann and Plus, 1996). 
Tolbutamide was tested in a long-term bioassay (NCI Carcinogenesis 
Bioassay 1978) but was found to exert no carcinogenic effect. Glibenclamide was well 
tolerated by various animal species like rats, rabbits and dogs, even after 
administration of very high doses (Kuhlmann and Plus, 1996). But the body weight 
gain was reduced, and red blood cells, hemoglobin and hematocrit were decreased 
besides, hepatic glycogen content and lipid droplets in liver cells were reduced in the 
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feeding of glibenclamide to the rabbits for 6 months (Kuhlmann and Plus, 1996). 
Reports of serious toxicity of glibenclamide have been extremely uncommon. One 
such report described a 67-year-old man who developed a hypersensitivity reaction 
while receiving 20-30 mg of glibenclamide per day for type II diabetes (Feldman, 
1985). However, 800 mg/kg per day glipizide administered orally to rats and dogs for 
1 year caused no toxic effects (Kuhlmann and Plus, 1996). But in some clinical 
therapy with sulfonylureas, such as glibenclamide, tolbutamide and chlorpropamide, 
the toxic-allergic side-effects and the syndrome of Inappropriate Secretion of 
Antidiuretic Hormone (SIADH-Syndrome), hypoglycaemia and some clinical 
symptoms of hyponatraemia appeared in the patients with type II diabetic (Berger, 
1985). 
In summary, sulfonylurea drugs have many actions on pancreatic p cells, 
vascular smooth muscle cells, cardiac myocytes and many other cells. The action of 
sulfonylureas are mainly mediated through blockade of the KAip channels. Although 
the administration with sulfonylureas cause some adverse effects, they are still 
commonly used in the clinical treatment of type II diabetic patients. 
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1.4. Objectives of the present study 
Various studies suggest that some sulfonylurea drugs such as glibenclamide 
show multiplicity of the cellular response in the cardiovascular system; they act not 
only as potent and selective blockers of vascular ATP-sensitive K+ channels (Standen 
et al., 1989), but also as muscle relaxants through undefined mechanisms. In view of 
the widespread use of sulfonylureas as ATP-sensitive K+ channel blockers, other 
cellular effects of these drugs may have affected the accuracy in evaluating a role of 
ATP-sensitive K+ channels in the vascular response. In addition, it is unclear about the 
impact of chronic medication with sulfonylurea drugs on the vascular function in type 
II diabetic patients who normally tend to develop some cardiovascular disorders. 
Therefore, it would be of great interest in detailed pharmacological investigation of 
the vascular response to some representative sulfonylurea drugs. There were four 
major objectives in the present study: (1) to investigate the hypothesis that 
endothelium-derived relaxing factors such as nitric oxide is involved in 
glibenclamide-induced endothelium-dependent relaxation in rat blood vessels, and the 
presence of the functional endothelium may have underestimated the importance of 
KATP channels in the regulation of membrane potential, muscle contractility and 
vascular tone when glibenclamide is used as a selective blocker of KAip channels. 
Therefore, the effect of glibenclamide on endothelial [Ca^^] and on tissue contents of 
cyclic GMP in endothelium-intact arteries would be examined. (2) To investigate the 
hypothesis that glibenclamide-induced endothelium-independent relaxation is 
mediated by inhibition of Ca】+ influx through plasma membrane Ca】+ channels in 
vascular smooth muscle or by Ca^^-independent mechanisms such as inhibition of 
protein kinase C-dependent pathway involved in excitation-contraction coupling. (3) 
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To investigate the hypothesis that glibenclamide could inhibit proliferation of arterial 
smooth muscle cells or promote proliferation of vascular endothelial cells. (4) To 
investigate the hypothesis that tolbutamide-induced contraction is mediated through 
Ca2+ influx through either voltage-sensitive Ca】+ channels or non-selective cation 
channels in arterial smooth muscle cells. A combination of experimental approaches 
were used in order to achieve aforementioned objectives (Fig. 4); they include force 
measurement, cell culture, immunostaining, Ca〗+ fluorescence measurement, 
radioimmunoassay of cyclic nucleotide, and cell proliferation. These studies should 
provide novel information regarding the KAip channel-independent vascular action of 
sulfonylurea drugs, such as glibenclamide, glipizide and tolbutamide. 
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Figure 4 
The proposed mechanism involved in the glibenclamide-induced relaxant response in 
blood vessels. (1) Glibenclamide may increase endothelial [Ca】+], (2) glbienclamdie 
may inhibit Ca〗+ influx via voltage-dependent Ca〗+ channel in arterial smooth muscle, 
and (3) glbienclamide may interfere with protein kinase C-mediated contractile 
mechanisms. NOS: nitric oxide synthase; G: G protein; PIP2: phosphatidylinositol 4,5-
bisphosphate; DAG: diacylglycerol; PKC: protein kinase C; GC: guanylate cyclase; 
cGMP: cyclic guanosine monophosphate; PKG: cGMP-dependent protein kinase. 
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Chapter 2 Methods and Materials 
2.1. Tissue and Cell Preparation 
2JJ. Preparation ofthe isolated rat aorta and mesenteric artery 
Male Sprague-Dawley rats of body weight about 300-350 g (supplied by 
Animal Services Center, Chinese University of Hong Kong, Hong Kong) were used in 
this study. They were killed by cervical dislocation and bled. The rat thoracic aorta 
and mesenteric artery were carefully removed and then placed into fresh oxygenated 
Krebs-Henseleit solution. Under a light microscope, the vessels were cleaned of 
adhering adipose and connective tissues, and then cut into ring segments of 
approximately 4 mm in length for the aorta and 3 mm in length for the mesenteric 
artery. Three rings of thoracic aorta and mesenteric artery, either with endothelium or 
without endothelium, were prepared from each rat for recording of isometric tension. 
Each group of experiments were performed on arteries from different rats. The use of 
rats was approved by the Animal Ethics Committee, Chinese University of Hong 
Kong. 
2.L2. Removal of the functional endothelium 
hi some tissues, the endothelial layer was mechanically disrupted by gently 
mbbing the intimal surface of an arterial ring back and forth several times with a 
plastic tubing. Successful removal of the functional endothelium was confirmed by 
the absence ofarelaxant response to acetylcholine (0.3 ^iM for the aorta and 1 ^ iM for 
the mesenteric artery), an endothelium-dependent vasodilator (Furchgott and 
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Zawadzki, 1980). Endothelium integrity or denuation was also evaluated by light 
microscopy of the histological section ofanartery. 
2,L3. Cell culture 
2.1.3.1. Materials 
Collagenase Collagenase (Type IA) Sigma, USA 
DMEM Dulbecco's Modified Eagle Medium Gibco, USA 
FBS — Fetal Bovine Serum Gibco，USA 
PBS ^ulbecco's Phosphate-Buffered Saline Gibco, USA 
PS Penicillin-Streptomycin Gibco, USA 
RPMI ~ ~ RPMI Medium 1640 Gibco, USA 
Trypsin Trypsin-EDTA (lx, 0.25 %) ' Gibco, USA 
2.1.3.2. Aortic smooth muscle cells in primary culture 
Male Sprague-Dawley rats of approximately 300-350 g were killed by pure 
carbon dioxide. The thoracic aorta was rapidly removed and kept immediately in ice-
cold PBS. The connective tissue and surrounding adipose tissue were trimmed off and 
the endothelial layer was mechanically removed by rubbing the lumen of the artery 
with plastic tubing. The artery was then cut into segments of approximately 4-mm in 
length. The lumen was cut open and washed twice with PBS. The tissues were then 
placed into a 25 cm^ culture flask (Costar, Cambridge, MA, USA) with modified 
DMEM (10% FBS + 2x PS) and incubated at 37 °C under 5% CO2 condition. After 
three-day incubation, tissues and culture medium were removed. The cells were 
washed with PBS and then with fresh DMEM. The cells were kept in an incubator, 
and culture medium was replaced with fresh medium once every two days until a 
confluence layer of vascular smooth muscle cells was formed (Fig. 5A). 
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Figure 5 
Photomicrographs of (A) rat aortic smooth muscle cells in primary culture 4 days after 
isolation, (B) rat aortic endothelial cells in primary culture 2 days after isolation, (C) 
cultured rat aortic smooth muscle cell line (A7r5) and (D) cultured human umbilical 
cord vein endothelial cell line (ECV-304). 
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2.1.3.3. Aortic endothelial cells in primary culture 
Male Sprague-Dawley rats of approximately 300-350 g were killed by pure 
carbon dioxide. The thoracic aorta was removed and placed immediately in ice-cold 
PBS. The connective tissue and surrounding adipose tissue were trimmed off. The artery 
was cut longitudinally into a long sheet-shape. After gently washing the artery twice in 
PBS, tissues were placed into a 25 cm^ culture flask (Costar, Cambridge, MA, USA) 
with 0.2% collagenase in PBS (w/v) (Pearson et al., 1978). Flask was shaken in a 
shaking water bath at 37 °C for 15 min. The tissues were removed and the cell mixture 
was transferred to a 15-ml conical tube (Falcon, Becton Dickinson Labware, NJ, USA) 
and centrifuged at 800 g for 5 min. The supernatant was drain away and the cells were 
resuspended in 5 ml of RPMI (10% FBS + 2x PS). The entire cell suspension was 
planted in a 25 cm^ culture flask and then incubated at 37 °C with 5% CO2 condition for 
1 hour and washed with fresh RPMI. The cells were cultured with culture medium 
replaced twice a week until a confluence layer of endothelial cells was obtained (Fig. 
5B). The endothelial cells after 3 days culture were confirmed by their positive reactivity 
to antibody against Von Willebrand factor (Dako A/S, Denmark). 
2.1.3.4. Cultured rat aortic smooth muscle cell line (A7r5) 
BDIX rat thoracic aortic smooth muscle cell line, A7r5 (CRL-1444) was 
purchased from American Type Culture Collection (ATCC, Bethesda, MD, USA). 
The cells were grown in DMEM supplemented with 10% FBS and l x PS in a 
humidified atmosphere (5% CO2) at 37 °C. Culture medium was changed twice a 
week until the cells became approximately 80-100% confluent (Fig. 5C). 
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2.1.3.5. Cultured human umbilical vein endothelial cell line (ECV-304) 
Human umbilical cord vein endothelial cell line, ECV-304 (CRL-1998) was 
obtained from American Type Culture Collection (ATCC, Bethesda, MD, USA). The 
cells were grown in RPMI supplemented with 10% FBS and lx PS in a humidified 
atmosphere (5% CO2) at 37 °C. Culture medium was replaced every 2 days until the 
cells became approximately 80-100% confluent (Fig. 5D). 
2.1.3.6. Cell subculture 
Culture medium was removed and the cells were washed with PBS. Trypsin 
(0.25%)-containing solution 2 ml was added to a culture flask and the flask was 
allowed to sit at room temperature (or incubate at 37 °C) for 10 minutes. A fresh 
medium (DMEM for smooth muscle cell; RPMI for endothelial cell) was added to 
disperse clusters of cells. The concentration of the cell suspension was determined by 
a hemacytometer (Sigma, MO, USA) i f necessary. The cells were dispersed to new 
culture flasks. 
2.1.3.7. Immunostaining of endothelial cells in primary culture 
The identity of primarily cultured rat aortic endothelial cells was confirmed 
by immunostaining using an antibody against Von Willebrand factor (Dako A/S, 
Denmark). The cultured cells grown in chamber slides O^unc, IL, USA) were fixed in 
40/0 formaldehyde in PBS for 2 hours, and blocked with 1% BSA (Bovine serum 
albumin) in PBS for 30 min. The cells were then stained with a polyclonal antibody 
against human Von Willebrand factor (dilution: 1:400 in PBS with 1% BSA) 
overnight at 4 °C. The slides were then washed in PBS, and then incubated with FITC-
labeled goat anti-rabbit IgG for 1 hour. For controls, some slides were incubated in 
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1% BSA in PBS without the primary antibody. Some slides were counter-stained with 
0.00003% DAPI in 0.9% NaCl. After washing in PBS, the slides were mounted in 
glycerol and examined under a fluorescence microscope (Zeiss Axiophot 2). The 
results indicate that over 98% of the cells are positively stained, showing the cultured 
cells were of endothelial origin (Fig. 6). 
2.2. Organ Bath Set-up 
After tissue preparation, each arterial ring was mounted between two fine 
stainless steel pins (100 ^im in diameter) submerged in an organ bath. One of the steel 
pins was connected to a force-displacement transducer (FT-03, Grass Instruments Co., 
Quincy, MA, USA), while the other was fixed to a built-in support at the bottom of 
the organ bath. Changes in isometric force were recorded, and either displayed on a 
chart recorder or stored using a Maclab software (version 3.5). The diagram in Fig. 7 
illustrates a set-up for contractile force measurement. 
Each ring was kept in a temperature-regulated 10-ml organ bath containing 
Krebs-Henseleit solution. The bath solution was maintained at 37 °C and continuously 
gassed with a mixture of 95% O2 and 5% CO2 to give a pH of 7.3-7.4. 
Arterial rings were suspended optimally under an initial passive resting 
tension of 1 g for the aorta and 0.5 g for the mesenteric arteries, which had been 
determined by length-tension relationships. Tissues were allowed to equilibrate for 
about 60 min during which time the bath solution was replaced with pre-warmed 
Krebs solution every 20 min. During these wash procedures, the basal tone was 
usually deviated from the resting level, so it was readjusted to the optimal level 
whenever necessary. 
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Diagrammatic illustration of isometric force measurement. An artery ring was 
mounted in an organ bath and changes in contractile force were detected by a Grass 
force transducer. 
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2.3. Force Measurement 
Thirty minutes after being set up in the organ bath, the preparations were 
first contracted with a single concentration of 60 mM K+ to test their contractile 
response. Arterial preparations that produced a contraction of above 1 g in aorta or 0.5 
g in mesenteric arteries, in response to high K+ solution were chosen for this study. 
Removal of the endothelium was verified by the lack of relaxant response to 
acetylcholine. In contrast, acetylcholine (1 ^iM) relaxed by over 80% phenylephrine-
precontracted arteries indicates the presence of functional endothelium. Thereafter, the 
tissues were washed several times with Krebs-Henseleit solution until muscle tension 
returned to the basal level. 
2J.L Vascular action of glibenclamide 
2.3.1.1. Antagonistic effect ofglibenclamide on relaxation induced by K^ channel 
openers 
The rings of both endothelium-intact and -denuded mesenteric arteries were 
first contracted with phenylephrine to establish a sustained contraction and then totally 
relaxed by 30 ^iM pinacidil, the K+ channel opener. Under this condition, 
glibenclamide (0.03-1 ^iM) was applied cumulatively to the bath solution to induce a 
concentration-dependent recovery of muscle tension. In another set of experiments, 
the concentration-relaxation relationship for pinacidil or cromakalim was constructed 
and compared in the absence and presence of glibenclamide. The tissues were exposed 
to glibenclamide at various concentrations for 30 min prior to application of 
constrictor. 
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2.3.1.2. Relaxant response of glibenclamide 
Following the equilibration period, the contractile response of the rat 
thoracic aortic rings or mesenteric artery rings were elicited by 0.3 f iM or 3 | iM 
phenylephrine, respectively. In the endothelium-denuded arteries, the concentration of 
phenylephrine was lowered (0.1 ^iM for aorta and 1 |aM for mesenteric artery) in order 
to match the magnitude of contraction in the endothelium-intact arteries. After a 
contraction response reached a steady level, glibenclamide was applied cumulatively 
to induce a concentration-dependent response in both endothelium-intact and -
denuded arteries. The effect of glibenclamide on the basal tone was also tested. 
2.3.1.3. Role of endothelium-derived vasoactive factors in glibenclamide-induced 
relaxation 
In this group ofexperiments, the effects of inhibitors of endothelium-derived 
relaxing factor/nitric oxide were examined on the glibenclamide-induced relaxation. 
Arterial rings with the functional endothelium were first incubated with each inhibitor 
(1-3 ^iM methylene blue, 10-100 ^ M N°-nitro-L-arginine and 3-100 ^iM N^-nitro-L-
arginine methyl ester) for 20 minutes before they were contracted with phenylephrine 
to establish a sustained tone, glibenclamide was then applied cumulatively to induce a 
c o n c e n t r a t i o n - d e p e n d e n t relaxation. In addition, the effects of inhibitors for nitric 
oxide-dependent dilation were tested on the relaxation induced by known 
endothelium-dependent vasodilators, such as acetylcholine or A23187. 
In another set of experiments, the tissues would first contracted with 
phenylephrine, then a single dose of glibenclamide (100 or 300 ^iM) was used to 
completely relax the arteries. The reversal effect of each inhibitor of nitric oxide 
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activity was examined on the relaxation induced by glibenclamide or by sodium 
nitroprusside (1 ^iM). 
In some experiments, the possible antagonism of L-arginine on the effect of 
L-NAME was also investigated. Tissues were first exposed to L-arginine (1 or 3 mM) 
for 10 min before addition of L-NAME (20 min contact time), the relaxant effect of 
glibenclamide was then tested in the phenylephrine-contracted arteries. 
2.3.1.4. Effect of endothelial prostanoids in glibenclamide-induced relaxation 
Indomethacin, an inhibitor of cyclooxygenase, suppresses production of 
prostacyclin in the endothelial cells. To examine the possible role of endothelial 
prostacyclin in the glibenclamide-induced relaxation, the endothelium-intact aorta and 
mesenteric arteries were exposed to indomethacin for 20 min prior to addition of 
phenylephrine. When the steady contraction was achieved, glibenclamide was added 
cumulatively into the bath solution to induce a concentration-related response. 
2.3.1.5. Effects of putative K^ channel blockers on glibenclamide-induced 
relaxation 
Since endothelial cells also liberate hyperpolarizing factors which could 
cause relaxation of the underlying vascular smooth muscle cells, and nitric oxide 
could increase K+ conductance in smooth muscle, it is worthwhile examining the 
possibility that glibenclamide may also affect K+ channel activity. The arterial rings 
were first contracted with phenylephrine and then fully relaxed by glibenclamide (100 
or 300 p,M). The effect of each putative K+ channel blockers (charybdotoxin 100 nM, 
apamin 100 nM, tetraethylammonium ions 1 mM and 4-aminopyridine 1 mM) was 
examined to see whether the relaxant effect of glibenclamide could be reversed. 
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2.3.1.6. Effect of glibenclamide on high K^- and CaCl2-induced contraction 
In the first set of experiments, the endothelium-intact thoracic aorta or 
mesenteric artery rings were contracted with 60 mM K+ to reach a steady tension, 
glibenclamide was then applied cumulatively to the bath to cause a concentration-
dependent response. The high K+ solution was prepared by substituting Na+ with an 
equimolar concentration of K+. 
In the second set of experiments, the rings were contracted with external K+ 
(5.9-60 mM) added cumulatively to obtain the first concentration-response curve. 
Once the maximum response to the high K+ had been achieved, tissues were rinsed 
with Krebs solution every 20 min until the muscle tone returned to the basal level. 
They were then equilibrated with glibenclamide (30-300 ^iM) for 30 min and another 
cumulative concentration-contraction curve for external K+ was repeated. 
In the last set of experiments, the possible inhibitory effect of glibenclamide on 
Ca2+ influx was examined in endothelium-denuded vessels. The artery rings were 
stimulated first with 1 ^iM phenylephrine in a Ca^^-free Krebs solution containing 0.5 
mM Na2-EGTA to deplete intracellular Ca〗+ stores and then rinsed with a Ca^^-free 
solution without EGTA several times until the resting tension was maintained or 
readjusted. The control cumulative concentration-response curve for CaCl2 was obtained 
in a Ca2+-free 60 mM K+ solution and the tissue was then washed first in a Ca^^-free 
solution and then in a Ca^^-free 60 mM K+ solution every 20 min until the basal tone 
was restored. The second concentration-response curve for CaCl2 was repeated in the 
absence and presence of 30-300 ^iM glibenclamide (30 min contact time). Contractions 
were presented as mN. The effect of the L-type voltage-sensitive Ca?+ channel inhibitor, 
nifedipine (10 nM), was also tested. 
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2.3.1.7. Effect of glibenclamide on prostaglandin F2crinduced contraction 
The endothelium-intact mesenteric arteries were first contracted with 30 nM 
9,ll-dideoxy-lla,9a-epoxymethanoprostaglandin F2a (U46619) to establish a 
sustained tone, glibenclamide was then applied cumulatively to the organ bath to 
induce a concentration-dependent response. The effect of glibenclamide on U46619-
induced contraction was compared with that on contraction induced by other 
constrictors, such as phenylephrine, protein kinase C activator and high K+. 
2.3.1.8. Effect of glibenclamide on protein kinase C-mediated contraction 
In order to gain information that whether glibenclamide may also interfere 
with Ca2+-independent contractile mechanisms such as activation of protein kinase C 
in vascular smooth muscle cells, the effect of glibenclamide was examined on phorbol 
12,13-diacetate (PDA)-induced sustained increase of muscle tension. The artery rings 
were first incubated for 20 min in a Ca^^-free solution containing 0.3 mM Na2-EGTA 
and washed with the same solution twice before addition of 1 ^iM PDA, the protein 
kinase activator. Once a sustained tension was obtained, glibenclamide was applied 
cumulatively. In control experiments, the effect of staurosporine, the inhibitor of 
protein kinase, was tested on the PDA-induced contraction. 
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2.3.2, Vascular action of glipizide 
Following the equilibration period, the contractile response of the rat 
endothelium-intact mesenteric artery rings were elicited by addition of different 
contractors, 1 f iM phenylephrine or 60 mM K+ or 30 nM U46619, respectively, in 
normal Krebs-Henseleit solution, or 1 ^iM PDA in a Ca】+ free Krebs-Henseleit. After 
a steady tone was achieved, glizipide was added cumulatively to the bath solution. 
These experiments were conducted in endothelium-denuded rat mesenteric arteries. 
2.3.3, Vascular action of tolbutamide 
2.3.3.1. Contractile response of tolbutamide 
The contractile response of tolbutamide was examined in the rat aorta and 
mesenteric artery rings. After 1 ^iM phenylephrine or 60 mM K+ was used to establish 
a sustained tone, tolbutamide (1-5 mM) was then added cumulatively. 
The effect of tolbutamide (1-5 mM) alone was also tested on the basal 
tension of the isolated arteries with and without the functional endothelium. 
2.3.3.2. Effects of inhibitors of endothelium-derived factors 
A sustained tension of an artery ring was induced by tolbutamide (5 mM), 
the inhibitor of endothelin I (EAi) receptor antagonist, BQ610 (200 nM), was added to 
the bath solution. The effect of BQ610 (100-200 nM) was also examined on 
endothelin I (10 nM)-induced sustained contraction. In addition, the effect of 
indomethacin (10 ^iM) or L-NNA (100 ^iM) were also examined on the tolbutamide-
induced contraction. 
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2.3.3.3. Effects of inhibitors of Ca^^ influx 
The concentration-dependent contractile response to tolbutamide (0.1-5 mM) 
in rat arteries were examined in the presence and absence of extracellular Ca】+. In 
experiments using a Ca^^-free solution, 0.5 mM Na2-EGTA was added. 
In order to investigate whether tolbutamide-induced sustained contraction 
was due to its stimulatory effect of Ca〗+ entry, the effects of nidefipine (1 |aM, a 
voltage-gated Ca^^ channel blcoker), cadmium chloride (500 i^M，a non-selective Ca】+ 
channel blocker) or nickel sulphate (300 ^iM, a non-selective Ca:+ influx inhibitor), 
were evaluated. 
Besides, thapsigargin (30 nM), an endoplasmic reticulum Ca^^-ATPase 
inhibitor, was also examined on the tolbutamide-induced conatrction. 
2.3.3.4. Effect of protein kinase C inhibitor 
Once a sustained tension was developed by 5 mM tolbutamide, 
staurosporine (30 nM), a protein kinase C inhibitor, was added to the bath to test its 
effect on tolbutamide-induced contraction. This effect was compared with the effect 
of staurosporine on the PDA-induced contraction. 
2.3.3.5. Effects of neural factors 
After a sustained contractile response to either 5 mM tolbutamide or 1 ^iM 
phenylephrine was obtained, prazosin (1 ^iM), an ai-adrenoceptor antagonist, was 
applied to examine whether tolbutamide could stimulate sympathetic transmission. 
In some experiments, the arterial tissues were incubated for 20 min with 10 
fiM guanethidine, an adrenergic neurone blocker used to inhibit noradrenaline release, 
or for 1 hour with a neurotoxin, 6-hydroxydropamine hydrobromide (6-OHDA, 3 
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fiM)，before addition of 5 mM tolbutamide. The possible effects of these two agents 
were compared with response of tolbutamide in untreated tissues. 
2.4. cyclic GMP measurement 
2.4.1, Material 
—cGMP [12¾ Assay Kit | Amersham U.K. | 
2.4.2. Methods 
2.4.2.1. Tissue preparation 
The aortic rings were placed in organ baths at 37 °C as described in section 
2.2. After necessary pharmacological treatment (see below), the tissues were rapidly 
removed, frozen in liquid nitrogen and then kept at -70 °C for later measurement of 
cyclic GMP contents. 
2.4.2.2. Plasma and tissue according to protocols provided byAmersham 
1. Homogenize frozen tissue in cold 6% trichloroacetic acid at 4 °C to give a 
10% w/v homogenate. Add 40 p,l of 6% trichloroacetic acid in 5 times, in 
order to homogenize all frozen tissue. 
2. Centrifuge at 3300 rpm for 15 min at 4 °C. 
3. Collect the supernatant fraction and discard the pellet. 
4. Keep 20 [d aliquot for protein content measurement. 
5. Wash the supernatant 4 times with 5 volumes (1 ml) of water saturated 
diethyl ether. The upper ether layer was discarded after each wash. 
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6. The remaining aqueous extract was lyophilized or dried using SpeedVac 
Concentrator (Savant) and Flexi-Dry (FTS Systems, Stone Ridge, NY, 
USA). 
2.4.2.3. Cyclic GMP content measurement 
Cyclic GMP assay protocol is provided by Amersham. Leave the tissue at 
room temperature for 15 minutes, then add 1 ml (assay buffer) into each sample tube 
and mix well, then put the tubes into water bath (37 °C) for 15 min. 





Cyclic GMP standard (Acetylation standard): 
Label 7 tubes (Sl-S7), then add 500 ^il assay buffer into all tubes. 
Add 500 ^1 acetylation standard stock into S1 tube(128 fmol) and mix. 
^^^^ Transfer 500 ^il 
52 tube (64 fmol), mix. 
- U - Transfer 500 p,l 
53 tube (32 fmol), mix. 
- U - Transfer 500 ^il 
54 tube (16 fmol), mix. 
- L i - Transfer 500 ^il 
55 tube (8 fmol), mix. 
-=L> Transfer 500 p,l 
56 tube (4 fmol), mix. 
- U - Transfer 500 ^il 
57 tube (2 fmol), mix. 
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Day 1: 
1. Prepare 2 sets of new polypropylene tubes, including duplicate for total 
count (TC) and zero standard (Bo). 
2. Transfer 500 ^1 sample into each tube (first set). 
3. Pipette 500 p,l assay buffer into the zero standard (Bo) tubes. 
4. Prepare the acetylation reagent by mixing 1 volume of acetic anhydride 
with 2 volumes of triethylamine in a glass vessel and mix them well. 
5. Carefully add 25 p.1 of the acetylation reagent to all tubes containing 
standards and samples, and vortex immediately following addition of the 
acetylation reagent. 
6. Pipette 100 p,l aliquots from all tubes into the corresponding polypropylene 
tubes (second set). 
7. Pipette 100 p,l of antiserum into all tubes except for the TC. 
8. Vortex mix all tubes thoroughly and cover the tubes, for example with 
plastic and incubate for 1 hour at room temperature (22 °C). 
9. Pipette 100 ^il of ['^^I]cyclic GMP into all tubes. The TC should be 
stoppered and set aside for counting. 
10.Vortex mix all tubes thoroughly and cover the tubes and incubate for 
between 15-18 hours at 2-8 °C. 
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Dav2: 
11 .Gently shake and swirl the bottle of Amerlex-M second antibody reagent 
(blue-green) to ensure a homogenous suspension. Add 500 ^1 to each tube 
except for TC. 
12.Vortex mix all tubes thoroughly and incubate for 10 min at room 
temperature (22 °C). 
13.Separate the antibody bound fraction by using magnetic separation, as 
described below: 
Magnetic Separation: 
Attach the rack on to the Amerlex-M separator base and ensure that all 
tubes are in contact with the base plate. Leave for 15 min. After separation, do 
not remove the rack from the separator base. Pour off and discard the 
supernatant liquids. Keeping the separator inverted, place the tubes on a pad of 
absorbent tissues and allow to drain for 5 min. 
14.0n completion of the magnetic separation, firmly blot the rims ofthe tubes 
on the tissue pad to remove any adhering droplets of liquid. Do not re-invert 
the tubes once they have been turned upright. 
15.Determine the radioactivity present in each tube by counting for at least 60 
sec in a gamma scintillation counter (Kontron Gamma-I, Health Champ 
Ltd.). 
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2.4.2.4. Protein content measurement 




No. Protein Stock (^il) Water (^il) Protein Concentration (^g/ml) 
51 6.25 43.75 50 
52 12.5 37.5 100 
53 25 25 200 
54 37.5 12.5 300 
55 50 0 400 
56 0 50 0 
1. Prepare some new tubes. 
2. Transfer a 20 ^il sample into every tube. 
3. Then add 30 ^il water 
4. Mix well. 
5. Add 50 ^tl Lowery Reagent and vortex immediately. 
6. Add 25 ^1 Folia and Ciocaltaiphenol, and vortex immediately. 
7. Take absorbance reading of a blank 96 wells/plate on a spectropotometer 
(Spectra MAX 250, Molecular Devices Ltd., UK) by a Softmax Pro. 
(version 2.1.0). 
8. Finally, transfer 100 ^il from each sample and standard into a 96 wells/plate. 
Read the absorbance again. 
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2.4.2.5. Cyclic GMP measurement protocol 
After 60 min period of equilibration in the oxygenated Krebs solution at 37 °C, 
the arterial tissues were first incubated with phenylephrine for 10 min, then with 10 ^iM 
glibenclamide for 20 min in the absence and presence of L-NNA. At the end of the 
reaction, arterial rings were rapidly frozen in liquid nitrogen and stored at -70 °C until 
homogenized in 0.5 ml of ice-cold 6% trichloroacetic acid using a glass homogenizer. 
The total tissue contents of cyclic GMP were measured using radioimmunoassay. 
2.5. Ca2+ measurement 
2.5.7. Materials 
2.5.1.1. PTIRatioMaster Fluorescence System (Fig. 8) 
(1) Photon Multiply Tube (PMT) 
(2) Inverted microscope P^ikon ECLIPSE 300/Nikon) 
(3) 40X Nikon Fluor lens (extra long working distance) 
(4) Xenon arc lamp 
(5) Software: Felix (version 1.11) 
(Photon Technology Internal Inc., NJ, USA) 
(6) Fluorescence dye: 
Fura-2/AM (Molecular Probes, Eugene, OR, USA) 
Excitation wavelength = 340/380 nm 
Emission wavelength = 520 nm 
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Figure 8 
Schematic representation of a PTI RatioMaster Fluorescence System used for [Ca^^]i 
measurement. 
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2.5.1.2. Confocal Imaging System (Fig. 9) 
(1) Inverted microscope O^IKONMEA 114BA, Nikon) 
(2) 40X Nikon Plan Fluor Oil lens (40/1.3 oil) 
(3) UV Argon ion laser 
(4) Filter blocks : B1 and Open block 
(5) Motorized control software: CoMOS (version 7.0a) 
(BIO-RAD Microscience Ltd., USA) 
Off-line analyze software : MetaFluor (version 3.0) 
(Universal Imaging Corp., NH, USA) 
(6) Fluorescence dye: 
Fluo-3/AM (Molecular Probes, Eugene, OR, USA) 
Excitation wavelength = 488 nm 
Emission wavelength > 510 nm 
2.5.2. Method 
Before plating cells (smooth muscle cells or endothelial cells) on 25-mm 
glass coverslips (Fisher Scientific Ltd.), which were sterilized by 95% ethanol, the 
coverslips were placed in the center of 35 mm petri dishes (Falcon, Becton Dickinson 
Labware, NJ, USA). After that, 10^  cells were seeded on the coverslips with 2 ml 
culture medium (DMEM or RPMI) and incubated at 37 °C with 5% CO2 for 1-2 days 
until a confluence layer was obtained (Fig. 10). 
Prior to measurement of [Ca^^]i, the medium in petri dish was discarded and 
replaced with 2 ml Krebs-Henseleit solution. A mixture of 6 ^il of 1 mM fluorescence 
dye (Fura-2/AM or Fluo-3/AM) and 6 fil of 0.53 mM pluronic acid was added into the 
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Figure 9 
Schematic illustration of a Confocal Imaging System (BIO-RAD MRC-1000) with 





(a) Ca2+ mesurement J >v (b) Cell proliferation 
CH T^ Glass coverslip V^ 
/ x ^ 
‘ f I 2 3 4 5 5 7 8 9 10 11 12、 
A〇0〇〇〇00〇〇0〇0 ,^====X B〇〇〇〇〇〇〇〇〇〇〇〇 
^ = ^ 10,000 cells c〇〇〇〇〇〇〇〇o〇o〇 5,000 cells 
^ ^ 2mlmedium 〖888888888888 l _ l m e d i u m 
p ,^,. .., F〇〇〇〇〇〇〇oo〇〇〇 50ul XTT 
Petnc dish G〇〇〇〇〇〇〇〇〇〇〇〇 
l^ HpOOOOOOOOOOO ) 
96 wel-plate 
Figure 10 
Diagrammatic illustration for preparation of seeding the cells for (a) Ca?+ 
measurement: glass coverslip grown with cells was adhered to the bottom of the petri 
dish with 2 ml culture medium incubated for 1-2 day, and for (b) cell proliferation: 
5xlO^ cells/well was seeded into a 96-well flat-bottomed plate and incubated for a 
period of time. 
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Krebs-Henseleit solution, giving a final concentration of 3 fiM. Cells were incubated 
with fluorescence dye for 45 min. After dye loading, the cells were rinsed with the 
Krebs-Henseleit solution three times, then the coverslip was transferred into a 
chamber which was used for [Ca^^]i measurement in PTI RatioMaster Fluorescence 
System or Confocal Imaging System. 
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2,5,3. Protocols for Ca measurement 
2.5.3.1. Effect ofglibenclamide in endothelial cells 
After dye loading, glibenclamide (1-100 ^iM) was added cumulatively into a 
chamber filled with Krebs-Henseleit solution to see the change in intracellular Ca?+ 
concentration. In another set of experiments, 30 ^iM glibenclamide was used to cause 
a steady increase of endothelial [Ca^^]i, then the bath solution was changed to a Ca^^-
free solution with an addition of 3 mM Na2-EGTA (free [Ca】+] was about 0.28 | iM 
under this condition, using Eqcal software, Cambridge, U.K.). 
2.5.3.2. Effect ofglibenclamide in vascular smooth muscle cells 
Since glibenclamide caused an endothelium-independent relaxation of the 
high K+-contracted arteries, it is worthy to examine a possible inhibitory effect of 
glibenclamide on Ca〗+ influx in aortic smooth muscle cells. The cultured aortic cells 
(cell line A7r5) were stimulated by 60 mM K+ to produce a biphasic increase of 
intracellular [Ca】+]. The effect of glibenclamide (30 ^iM) was tested on the sustained 
rise of intracellular [Ca〗+] in response to high K+. The effect ofthe voltage-sensitive 
Ca2+ channel blocker, nifedipine (100 nM) was also examined as control. 
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2.5.3.3. Effect of tolbutamide in vascular smooth muscle cells 
Tolbutamide induced an increase in force of the rat arteries, suggesting that 
^1 
tolbutamide may stimulate Ca influx across the smooth muscle cell membrane. 
Therefore, the possible effect of tolbutamide on the basal intracellular [Ca^^] was 
examined. In another set of experiments, 5 mM tolbutamide was used to cause a 
steady increase in smooth muscle [Ca^^]j, then the bath solution was changed to a 
Ca2+-free solution with an addition of 3 mM Na2-EGTA (free [Ca】+] was about 0.28 
^iM under this condition). The effect of the non-selective cation channel blocker, 
nickel sulphate (1 mM) was also examined on the [Ca^^]i-elevating effect of 
tolbutamide. 
2.6. Cell proliferation 
2,6A, Materials 
Cell Proliferation Kit I I (XTT) Boehringer Mannheim 
2,6.2. Method 
The endothelial cells or smooth muscle cells (5xlO^ cell/well) were cultured 
in a volume of 100 ^il RPMI (10% FBS + l x PS) or 100 ^1 DMEM (10% FBS + l x 
PS), in a 96-well flat-bottomed plate (Falcon, Becton Dickinson Labware, NJ, USA) 
shown in Fig. 10. They were incubated at 37 °C under a 5% CO2 condition for one 
day. Drug at desired concentrations after being filtered was added to each well. The 
endothelial cells were incubated for another day or smooth muscle cells for four days, 
50 \i\ XTT mixture (5 ml XTT labeling reagent + 0.1 ml electron-coupling reagent) 
was added to each well. The plate was then incubated for another 2-5 hours 
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(depending on the metabolic activity of the cells). Absorbance was read on a 
spectrophotometer (Spectra MAX 250, Molecular Devices Ltd., UK) by a Softmax 
Pro. (version 2.1.0) at a wavelength of 450 nm and a reference wavelength of 690 nm 
was subtracted. Each plate contained appropriate blank control wells containing 
medium, XTT and cells but no drugs. 
2,63, Protocols for cell proliferation 
2.6.3.1. Effect of glibenclamide on endothelial cell proliferation 
The human umbilical vein endothelial cells (ECV-304) at a density of 5xlO^ 
cells/well were incubated for one day with different drugs, such as glibenclamide (1-
广 
100 ^iM), inhibitors of nitric oxide activity (methylene blue 3 ^iM, N -nitro-L-arginine 
methyl ester 10 ^iM), nitric oxide donor or precursor (sodium nitroprusside 10 ^iM and 
L-arginine 1 mM), cGMP analog (8-Bromo-cGMP 1 mM) and cGMP-dependent 
protein kinase inhibitor (Rp-8-pCPT-cGMPs triethylamine 10 ^iM), which was added 
individually into each well of a 96-well plate. 
2.6.3.2. Effect of glibenclamide on aortic smooth muscle cell proliferation 
The rat thoracic aortic smooth muscle cells (A7r5) at a density of 5xlO^ 
cells/well were incubated for four days with different drugs, such as glibenclamide (1-
300 ^iM), protein kinase C activator (PDA 0.5 ^M and 1 ^iM), ai-adrenoceptor 
agonist (phenylephrine 10 ^iM) or Ca!+ channel blocker (nifedipine 0.1- 1 ^iM). 
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2.7. Chemicals and solutions 
Table 2 contains a list of chemicals and drugs used in this study. They were 
purchased either from Sigma (Sigma Chemicals, St. Louis, MO, USA) or from RBI 
(Research Biochemicals International, Natick, MA, USA). The chemical safety for 
using these compounds was approved by the Safety Office, The Chinese University of 
Hong Kong, Hong Kong. 
Table 2 Chemicals and drugs 
Chemicals Description Solvent Source 
4-Aminopyridine Voltage-gated K+ channel blocker DMSO Sigma 
8-Bromo-cGMP sodium Analog ofcGMP H2O RBI 
9 , l l - D i d e o x y - l l a , 9 a - Prostaglandin F 2 a analogue DMSO Sigma 
epoxymethano- vasoconstrictor 
prostaglandin F2a 
6-Hydroxydopamine Neurotoxin, toxic to catecholaminergic H2O Sigma 
Hydrobromide nerve terminals, depleting catecholamines 
A23187 Calcium ionophore, DMSO Sigma 
endothelium-dependent dilator 
Acetylcholine Endothelium-dependent vasodilator H2O Sigma 
Apamin Blocker of small conductance DMSO RBI 
Ca2+-activated K+ channels 
BQ610 Endothelin-I (EAi) receptor antagonist ~ ~ H ^ m 
Cadmium chloride Non-selective Ca^^ channel blocker H2O Sigma 
Charybdotoxin Blocker of large conductance H2O Sigma 
Ca2+-activated K+ channel 
Cromakalim Activator of ATP-sensitive K^ channels DMSO Sigma 
Endothelin-1 ETA-endothelin receptor agonist H2O RBI 
Forskolin Adenylate cyclase activator H2O Sigma 
Glibenclamide Hypoglycaemic drug, blocker of KAip DMSO RBI 
(Glyburide) channels 
Glipizide Hypoglycemic drug, blocker of KAip DMSO RBI 
channels 
Guanethidine An adrenergic neurone blocker Dilute Sigma 
Ethanol 
Indomethacin Cyclooxygenase inhibitor DMSO Sigma 
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Chemicals Description Solvent Source 
L-Arginine Nitric oxide precursor H2O Sigma 
Methylene Blue Inhibitor of guanylate cyclase H2O Sigma 
Trihydrate 
— „ — — 
N -Nitro-L-Arginine Inhibitor of nitric oxide synthase H2O RBI 
methyl ester 
— 
N -Nitro-L-Arginine Inhibitor of nitric oxide synthase 0.15M HC1 Sigma 
Nickel Sulphate Non-selective cation channel blocker H2O Beijing Hua 
Gong Chong 
Nifedipine L-type voltage-gated Ca^^ channel blocker DMSO Sigma 
Pinacidil K+ channel opener DMSO RBI 
Phenylephrine HC1 ai-adrenoceptor agonist, vasoconstrictor H2O RBI 
Prazosin HC1 ai-adrenoceptor antagonist DMSO RBI 
Phorbol 12,13-diacetate Protein kinase C activator, vasoconstrictor DMSO RBI 
Rp-8-pCPT-cGMPs cGMP-dependent protein kinase inhibitor H ^ 551 
Triethylamine 
Sodium Nitroprusside Nitric oxide donor, vasodilator H2O Sigma 
Staurosporine Protein kinase C inhibitor DMSO RBI 
Tetraethylammonium Putative K+ channel blocker H2O Sigma 
Chloride 
Thapsigargin Inhibitor of endoplasmic reticulum DMSO RBI 
Ca2+-ATPase 
Tolbutamide Hypoglycemic drug, KAip channel blocker DMSO Sigma 
The drug stock solution was normally prepared and stored in distilled water or DMSO and 
further diluted in Krebs solution or DMSO to a desired concentration. 6-Hydroxydopamine 
hydrobromide, charybdotoxin, cromakalim, glibenclamide, indomethacin, methylene blue, 
nifedipine, prazosin, phorbol 12,13-diacetate, sodium nitroprusside, staurosporine and 
thapsigargin are light-sensitive, the stock solution was protected from light stimulation. 
49 
Table 3 Solutions 
6 0 m M K + 
K - H Ca2+free 6 0 m M K + Ca^+free 
(mM) (mM) (mM) (mM) 
N a C l “ ^ H 9 n 9 « ^ 
NaHCO3 25 25 25 25 
MgCl2.6H2O 1 1 1 1 
KC1 4.7 4.7 60 60 
KH2PO4 1-2 1.2 1-2 1.2 
CaCl2 2.5 0 2.5 0 
D-glucose 11.1 11.1 11.1 11.1 
Ascorb ic acid 0.28 0.28 0-28 - • 
The pH value ofthe bathing solution was maintained at 7.3-7.4 when the bath solution 
was continuously oxygenated with a mixture of 95% O2 plus 5% CO2 at 37 °C. 
2.8. Statistical analysis 
To study the effect of glibenclamide on the agonist-induced contraction, 
values of I C 5 0 and maximal relaxation were compared in the absence and presence of 
various pharmacological agents. The effect of vasodilators on the sustained tone were 
expressed as a percentage of the control value. Cumulative concentration-relaxation 
relations were analyzed with non-linear curve fitting by means of a logistic equation 
(Grafit, Erithacus Software Ltd.) and IC50 values were calculated as the drug 
concentration causing the half maximum relaxation. The data were presented as 
means 士 S.E.M. from n experiments. A level of probability of less than 0.05 obtained 
from paired or unpaired Student's Mest was regarded as significant. A one way 
ANOVA Student-Newman-Keuls test was used when more two treatments were 
compared. 
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Chapter 3 Results 
3.1. Glibenclamide 
3,LL Effect ofglibenclamide on the K^ channel activity 
Glibenclamide was previously shown to have an inhibitory effect on the 
activity of arterial KAiP channels and on K+ channel activator-induced relaxation in 
blood vessels (Standen et al., 1989). I examined whether glibenclamide reduced the 
relaxation induced by cromakalim and pinacidil, two K+ channel openers, in both 
endothelium-intact and -denuded rat isolated mesenteric arteries. Figure 11A show 
that glibenclamide (1 ^iM) competitively reduced the cromakalim-induced relaxation 
in mesenteric arteries with endothelium ( I C 5 0 : 114.4 士 5.5 nM, n=5 for control and 
934.4 士 109.7 nM, n=3 for glibenclamide). Removal of the functional endothelium 
reduced the relaxant effect ofcromakalim ( I C 5 0 : 253.3 士 4.1 nM, n=5 for control and 
2458.3 士 123.7 nM, n=5 for glibenclamide, P<0.05 compared with control). 
Glibenclamide (1 ^iM) reduced the cromakalim-induced relaxation by about 8.2-fold 
and about 9.7-fold in the presence and absence of endothelium. Similarly, 
glibenclamide at 1 ^ iM significantly attenuated the pinacidil-induced relaxant response 
in a competitive manner ( I C 5 0 with endothelium: 2 1 6 . 6 士 13.6 nM, n=9 for control 
and 2567.4 士 315.5 nM, n=8 for glibenclamide; I C 5 0 without endothelium: 806.5 士 
32.1 nM, n=4 for control and 4702.5 士 442 nM, n=6 for glibenclamide, P<0.05 
compared with respective control). Pretreament of arterial tissues with glibenclamide 
(0.03-1 ^iM) displaced to the right the concentration-relaxation curve for cromakalim 
(Table 4) or for pinacidil (Table 5) in a concentration-related fashion. 
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Figure 11 
Concentration-response curves for relaxation induced by cromakalim in the 
endothelium-intact (〇，n=5 for control; •，n=3 for 1 ^iM glibenclamide) and the 
endothelium-denuded (•，n=5 for control; •，n=5 for 1 ^iM glibenclamide) 
mesenteric arteries. (B) Concentration-response curves for relaxation induced by 
pinacidil in the endothelium-intact (〇，n=9 for control;參，n=8 for 1 ^iM 
glibenclamide) and endothelium-denuded (•，n=4 for control; •，n=6 for 1 pM 
glibenclamide) mesenteric arteries. Data are means 士 s.e. mean of n experiments. 
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Table 4 Effect of glibenclamide on the cromakalim-mediated relaxation 
+ Endothelium - Endothelium 
Glibenclamide (^M) ICsn (nM) n IC^ (nM) n 
0 1 1 4 . 4 士 5 . 5 5 2 5 3 . 3 土 4 . 1 5 
0.03 183.4士29.9 * 3 351.4土41.8 5 
0.1 199.0士 19.3 * 5 587.8 士40.0* 7 
0.3 397.4士48.8* 4 870.3±24.8* 6 
1 934.4士 109.7 * 3 2458.3 =hl23.7* 5 
The I C 5 0 values for the relaxant response to cromakalim in the absence and presence 
of glibenclamide (0.03-1 fiM) in rat mesenteric arteries with and without the 
functional endothelium. Cromakalim was able to induced a full relaxation in the 
presence of glibenclamide. Asterisks indicate significant difference from the control 
values (P<0.05). Results are means 士 s.e. mean of n experiments. 
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Table 5 Effect ofglibenclamide on the pinacidil-mediated relaxation 
+ Endothelium - Endothelium 
Glibenclamide ( _ ICjo (nM) n IC^ (nM) n 
0 216.6士 13.6 9 806.5士32.1 4 
0.1 476.8±18.1* 3 1608.8士51.6* 4 
0.3 1318.0土 102.6 * 5 2815.4士166* 4 
1 2567.4 士 315.5 • 8 4702.5 士 442 * 6 
The I C 5 0 values for the relaxant effect of pinacidil in absence and presence of 
glibenclamide (0.1-1 ^iM) in rat mesenteric arteries with and without the functional 
endothelium. Pinacidil was able to induce a full relaxation in the presence of 
glibenclamide. Asterisks indicate significant difference from the control values 
(P<0.05). Results are means 士 s.e. mean of n experiments. 
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In another set of experiments, after pinacidil (3 ^iM) fully relaxed both 
endothelium-intact and -denuded mesenteric arteries precontracted with 1 ^iM 
phenylephrine, addition of glibenclamide at 3 | iM reversed the relaxant effect of 
pinacidil. However, glibenclamide at 50 fiM caused a 87.3 士 4.4o/o relaxation in the 
endothelium-intact arteries (n=5, Fig. 12A), but it had a small inhibitory effect (17.5 士 
4.7% relaxation, n=6) on the sustained tension in endothelium-denuded arteries (Fig. 
12B). It is clearly shown in Fig. 12C that glibenclamide at 3 ^iM reversed about 80% 
of the pinacidil-induced relaxation in rat endothelium-intact mesenteric arteries, but 
this concentration of glibenclamide caused a complete reversal of the pinacidil-
induced relaxation in endothelium-denuded tissues. The threshold concentration of 
glibenclamide to antagonise the effect of pinacidil was higher for arteries with 
endothelium (0.1 _ than for those without endothelium (0.03 _ . The 
concentration at which glibenclamide produced the half-maximum reversal of the 
pinacidil-induced relaxation was 0.57 士 0.03 ^iM (n=7) and 0.17 士 0.02 ^iM (n=7), 
respectively, in the presence and absence of endothelium. These results indicate that 
the presence of intact endothelium may have partially inhibited the effect of K+ 
channel openers and thus reduced the sensitivity to glibenclamide for inhibiting the 
ATP-sensitive K+ channels in endothelium-intact arteries. 
3,1,2, Relaxant response of glibenclamide 
As shown in Fig. 12A, 3 ^ M glibenclamide partially reversed relaxation 
induced by pinacidil while 50 ^iM glibenclamide caused relaxation instead of further 
reversal effect in the pinacidil-relaxed endothelium-intact artery. In contrast, 
glibenclamide at 50 f iM had little effect on muscle tone developed by 3 ^iM 
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Figure 12 
Glibenclamide (3 ^M) reversal of the pinacidil-induced relaxation in phenylephrine-
contracted arteries with (A) and without (B) endothelium in a rat mesenteric artery. Further 
addition of glibenclamide (50 ^iM) induced greater reduction of the sustained tone in an 
endothelium-intact artery than in an endothelium-denuded artery. (C) Concentration-
response curves for the reversal effect of glibenclamide on the pinacidil-induced relaxation 
in arteries with endothelium (〇)and without endothelium ( • ) . Results are means 士 s.e. 
mean of 7 experiments. 
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glibenclamide. This fmding suggests that glibenclamide may have a muscle relaxant 
effect and the endothelium plays a role. The traces in Fig. 13 and 14 show a 
concentration-dependent relaxation induced by glibenclamide in the isolated rat 
mesenteric artery and thoracic aorta, respectively, in the presence (Fig. 13A & 14A) 
and absence (Fig. 13B & 14B) of the functional endothelium. It is evident that 
removal of the endothelium markedly attenuated the relaxant response to 
glibenclamide approximately by 51-fold in mesenteric arteries and by 11-fold in aortic 
rings (Fig. 15). The I C 5 0 values for the glibenclamide-induced relaxation were 4.4 土 
1.1 ^iM (with endothelium, n=8) and 226.1 士 44.2 | iM (without endothelium, n=7) 
(P<0.05, Fig. 15A) in rat mesenteric arteries; 31.8 士 3.7 ^iM (with endothelium, n=9) 
and 365.3 土 29.1 ^iM (without endothelium, n=6) {P<0.05, Fig. 15B) in aortic rings. 
In addition, glibenclamide was about 7 times more effective in relaxing rat mesenteric 
arteries than rat aorta by comparing the I C 5 0 values with both tissues (P<0.05), even 
though glibenclamide could produce a full relaxation in both arteries. 
3,L3. Effects of inhibitors of nitric oxide activity on glibenclamide-
induced relaxation 
The concentration-dependent relaxant effect of glibenclamide (Fig. 13) was 
significantly greater in an endothelium-intact than endothelium-denuded mesenteric 
artery, indicating that the endothelium-derived vasoactive factors may be involved. 
The traces in Fig. 16A and B show that both acetylcholine (1 ^iM) and glibenclamide 
(10 p-M) fully relaxed the phenylephrine-precontracted mesenteric artery with 
f~y 
endothelium, and 10 fiM N -nitro-L-arginine (L-NNA), an inhibitor of nitric oxide 
synthase, completely reversed the relaxation (n=5 in each case). The level of vessel 
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Figure 13 
The concentration-dependent relaxations induced by glibenclamide in 1 ^iM 
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The concentration-dependent relaxations induced by glibenclamide in phenylephrine-
precontracted aortic rings with endothelium (A) and without endothelium (B). 
Calibration bars apply to both records. 
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Figure 15 
Concentration-response curves for the relaxant effect of glibenclamide in the 
phenylephrine-contracted (A) mesenteric arteries (〇，n=8 with endothelium;參，n=7 
without endothelium) and (B) aortic rings (〇’ n=9 with endothelium; # , n=6 without 
endothelium). Data are means 士 s.e. mean of n experiments. 
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tone developed after addition of L-NNA was greater than the original tone developed 
by phenylephrine before addition of dilators, indicating that phenylephrine-induced 
contraction may have been smaller in the presence of endothelium. Indeed, a 
submaximal concentration of phenylephrine induced a larger contraction in the 
presence of 10 ^iM L-NNA than in the absence of L-NNA (data not shown). Lack of 
contracting effect ofL-NNA along indicates that the basal nitric oxide release may not 
affect the arterial response to phenylephrine. In contrast, L-NNA (10-30 ^lM) did not 
alter the relaxant response to the exogenous nitric oxide donor, sodium nitroprusside 
(SNP, 1 ^ iM) in the same preparation (Fig. 16C) and the similar effect was observed in 
arteries from four rats. A similar response was also recorded in rat aortic rings with 
endothelium (n=4, Fig. 17A). N^-nitro-L-arginine methyl ester (L-NAME, 10 ^iM), 
another inhibitor of endothelial nitric oxide synthase, totally reversed the relaxant 
response to 100-300 ^iM glibenclamide in a phenylephrine-precontracted aortic ring 
(n=3, Fig. 17B), whilst L-NAME at 100 ^iM did not affect the relaxation induced by 
100 nM SNP (Fig. 17A). The SNP-induced relaxation was fully reversed by 
methylene blue (MB, 10 ^iM) which is an inhibitor of guanylate cyclase and the nitric 
oxide-mediated relaxation (n=3, Fig. 17A). These data favour a role of 
endothelium/nitric oxide in the glibenclamide-induced relaxation in both arteries. 
To further examine this possibility, the effects of nitric oxide synthase 
inhibitors on the glibenclamide-induced relaxation were investigated. The trace in Fig. 
18B shows that L-NNA at 10 ^iM attenuated the relaxation induced by glibenclamide 
in comparison with the control (Fig. l8A). In this series of experiments, pretreatment 
of the tissue with L-NNA at three concentrations (10-100 ^iM) inhibited the 
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Figure 16 
Complete reversal by N°-nitro-L-arginine (L-NNA, 10 ^iM) of the acetylcholine (Ach, 
1 ^iM, A) and glibenclamide (10 fiM, B)-induced relaxation in endothelium-intact 
arteries. Sodium nitroprusside (SNP, 1 |iM) completely relaxed the arteries. (C) Lack 
ofeffect ofL-NNA (10-30 [ M ) on the relaxation-induced by SNP (1 pM). This series 
of experiments was performed with endothelium-intact rat mesenteric arteries. The 
arteries were contracted with 1 j iM phenylephrine. 
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Figure 17 
(A) Methylene blue (MB, 10 ^iM) but not N^-nitro-L-arginine methyl ester (L-NAME, 
100 |iM) reversed the relaxation induced by sodium nitroprusside (SNP) in a rat aortic 
ring. (B) L-NAME (10 ^iM) reversed the relaxation induced by glibenclamide (100-
300 ^iM). The endothelium-intact aortic rings were pre-contracted by 0.3 ^iM 
phenylephrine (Phe). 
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Figure 18 
Traces are representative records for the relaxant effect of glibenclamide in the 
phenylephrine-precontracted endothelium-intact mesenteric arteries for control (A) 
and in the presence of 10 ^iM N^-nitro-L-arginine (L-NNA, B). L-NNA was applied 
20 min before addition of phenylephrine (1 ^iM). 
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same potency (IC50: 4.7 士 1.2 ^iM, n=6 for control; 52.7 土 11.3 ^iM, n=10 for 10 ^iM 
L-NNA; 75.2 士 20.1 ^iM, n=7 for 30 ^iM L-NNA; 73.1 士 21.2 ^iM, n=6 for 100 ^iM L-
NNA, P<0.05 compared with control, Fig. 19A), indicating that 10 ^iM is the 
concentration at which L-NNA maximally inhibited the glibenclamide-induced nitric 
oxide-dependent relaxation. Similarly, pretreatment of the endothelium-intact aortic 
rings with L-NAME (3-100 ^iM) caused a significant shift to the right of the 
concentration-response curve for the relaxant effect of glibenclamide ( I C 5 0 : 3 1 . 8 土 3 . 7 
^iM, n=9 for control; 231.3 土 66.4 |iM，n=5 for 3 ^iM L-NAME; 441.4 土 60.5 ^iM, 
n=4 for 10 [ M L-NAME; 448.8 土 61.0 ^iM, n=5 for 100 ^iM L-NAME, P<0.05 
compared with control, Fig. 19B). Exposure of endothelium-intact tissues to 3 mM L-
arginine，the precursor of nitric oxide biosynthesis, enhanced the glibenclamide-
induced relaxation by approximately 5-fold ( I C 5 0 : 31.8 土 3.7 ^iM, n=9 for control; 5.6 
土 0.4 ^iM, n=6 for 3 mM L-arginine, P<0.05); on the other hand, it partially, but 
significantly, antagonised the inhibitory effect of 10 ^iM L-NAME ( I C 5 0 : 441.4 士 
60.5 ^iM, n=4 for 10 ^iM L-NAME; 19.8 土 4.0 ^iM, n=5 for L-arginine plus L-NAME, 
P<0.05, Fig. 20). 
Figure 21 shows that exposure of arterial tissues for 20 min to MB also 
inhibited the glibenclamide-induced relaxation in both mesenteric arteries ( I C 5 0 : 4 . 8 土 
1.5 nM, n=6 for control and 38.1 土 8.7 ^iM, n=6 for 1 ^iM MB, P<0.05, Fig. 21A) and 
aortic rings ( I C 5 0 : 31.8 土 3.7 ^iM, n=9 for control and 8 9 . 5 土 1 . 6 ^iM, n = 4 for 3 \iM 
MB, P<0.05, Fig. 21B). Glibenclamide was still able to produce a maximum 
relaxation ofboth arteries in the presence o fMB (Fig. 21). 
To confirm the effects of both L-NAME and MB are not non-specific, I 
examined their effects on the relaxant response to A23187, a calcium ionophone, and 
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Figure 19 
Concentration-response curves for the relaxant effect of glibenclamide in the 
endothelium-intact rat mesenteric arteries in the absence (〇，n=6) and presence of 
N°-nitro-L-arginine (L-NNA, 10 ^iM, • , n=10; 30 ^iM, _ , n=7; 100 pM, •，n=6). 
(B) Concentration-response curves for the relaxation induced by glibenclamide in the 
endothelium-intact aorta in the absence (〇，n=9) and presence of N^-nitro-L-arginine 
methyl ester (L-NAME, 3 ^iM,參，n=5; 10 ^iM, •，n=4; 100 ^M, •，n=5). The 
inhibitor at each concentration was added to the bath 20 min prior to application of 
phenylephrine. Data are means 土 s.e. mean of n experiments. 
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Figure 20 
Concentration-response curves for the relaxant effect of glibenclamide in 
phenylephrine-precontracted endothelium-intact aortic rings (〇，n=9 for control;參， 
n=4 for 10 ^iM L-NAME; • , n=6 for 3 mM L-arginine; •，n=5 for 3 mM L-arginine 
plus 10 fiM L-NAME). L-NAME was added to the bath 20 min prior to application of 
phenylephrine. L-arginine was added 10 min before L-NAME. Data are means ± s.e. 
mean for n experiments. 
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Figure 21 
Concentration-response curves for the relaxant effect of glibenclamide in the 
endothelium-intact (A) mesenteric arteries (〇，n=6 for control; •，n=6 for 1 ^iM 
methylene blue) and (B) aortic rings (〇，n=9 for control; •，n=4 for 3 ^iM methylene 
blue). Methylene blue (MB) was added to the bath 20 min prior to application of 
phenylephrine. Data are means 士 s.e. mean of n experiments. 
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SNP, an exogenous nitric oxide donor in rat aortic rings. Traces in Fig. 22 show a 
concentration-dependent relaxation induced by A23187 in the absence (Fig. 22A) and 
presence of 10 ^iM L-NAME (20 min contact time, Fig. 22B). A23187 is a nitric 
oxide-dependent vasodilator. L-NAME suppressed the A23187-induced relaxation 
with a significant reduction of the maximum relaxation ( I C 5 0 : 8.08 士 0 . 8 8 nM, Emax: 
1 0 0 士 5.8o/o, n=4 for control; I C 5 0 : 87.1 士 3.7 nM, Emax: 31.2 士 10.9o/o, n=5 in the 
presence of L-NAME, P<0.05 compared with control, Fig. 24A). Figure 23 shows a 
concentration-dependent relaxation induced by SNP for control (Fig. 23A) and in the 
presence of 10 ^ M L-NAME (Fig. 23B) or of 3 ^iM MB (Fig. 23C). Figure 24B 
shows that pretreatment with MB but not with L-NAME significantly displaced the 
concentration-relaxation curve for SNP to the right without an effect on the maximum 
response ( I C 5 0 : 4.86 士 0.25 nM, n=5 for control; IC50： 4.96 土 0.44 nM, n=6 in the 
presence of L-NAME, P>0.05 compared with control; 38.5 士 3.8 nM, n=7 in the 
presence of MB, F<0.05 compared with control, Fig. 24B). The results of these 
experiments support the notion that the inhibitors of nitric oxide activity specifically 
inhibited the glibenclamide-induced relaxation of rat mesenteric arteries and aortic 
rings, and endothelial nitric oxide was involved. 
3,L4. Role of endothelial relaxing prostanoids in glibenclamide-
induced relaxation 
Apart from nitric oxide acting as the main endothelium-derived relaxing 
factor, the endothelium also liberates other relaxing factors in response to various 
physiological stimuli. Such vasoactive factors include relaxing prostanoids like 
prostacyclin. Biosynthesis of prostacyclins in endothelium can be inhibited by 
69 
A23187 (nM) 




\ 30 ^ 
V _ ^ lOmin 
——^ 3 10 30 
* • • 寻 










Traces showing the relaxant effect of A23187 in phenylephrine-precontracted 
endothelium-intact thoracic aorta for control (A) and in the presence of 10 ^iM N°-
nitro-L-arginine methyl ester (L-NAME, B). L-NAME was added 20 min before 
application of phenylephrine. 
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Figure 23 
Traces showing the relaxant effect of sodium nitropmsside (SNP) in phenylephrine-p e ontracted endoth ium-intact aortic rings i  the ab ence (A) and resence of 10 ^iM N^-nitro-L-arginine e hyl s er (L-NAME, B) or of 3 ^iM methylen  blue (MB,C). Calibration bars  B lso pply to C. L-NAME or MB was appl ed 20 min beforeaddition of 1 ^iM phe ylephrine. 
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Figure 24 
Concentration-response curves for the relaxant effect of A23187 (〇，n=4 for control; 
•，n=5 for 10 ^iM L-NAME) and sodium nitroprusside (SNP,〇’ n=5 for control; • ， 
n=6 for 10 ^iM L-NAME; •，n=7 for 3 ^iM MB) in rat endothelium-intact aortic 
rings. Data are means 士 s.e. mean of n experiments. 
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indomethacin, an inhibitor of cyclooxygenase. In endothelium-intact tissues, 
glibenclamide caused relaxation in a concentration-dependent manner with I C 5 0 
values of 4.8 土 1.5 ^iM (n=6, Fig. 25A) in rat mesenteric arteries and 31.8 土 3.7 ^iM 
(n=9, Fig. 25B) in aortic rings. Indomethacin (3-10 ^iM, 20 min contact time) did not 
affect the vasorelaxant effect of glibenclamide ( I C 5 0 : 5 . 6 土 1 . 1 ^M, n = 4 with 
mesenteric arteries, Fig. 25A; 25.0 士 3.8 ^iM, n=4 with aortic rings, P>0.05, Fig. 
25B). 
3,1,5, Effect ofputative K^ channel blockers on glibenclamide-induced 
relaxation 
Since endothelial cells also secrete factors that cause membrane 
hyperpolarization (through activation of vascular K+ channels) of the underlying 
vascular smooth muscle fibres and thus reduce Ca〗+ influx and muscle contractility. In 
addition, nitric oxide may also increase vascular K+ conductance. It is therefore 
worthwhile testing whether glibenclamide-induced relaxation may be in part mediated 
through activation of K+ channels. I examined the possible effects of various putative 
blockers of K+ channels on glibenclamide-induced relaxation in rat mesenteric 
arteries. It was found that the K+ channels blockers such as tetraethylammonium ions 
(TEA+，1 mM), 4-aminopyridine (4-AP, 1 mM), charybdotoxin (CTX, 100 nM) and 
apamin (100 nM), did not reverse the relaxant response to glibenclamide in rat 
mesenteric arteries (n=4 in each cases). In rat endothelium-intact aorta, TEA+ (1 mM) 
caused a 20% reversal of glibenclamide (300 ^iM)-induced relaxation (n=4). 
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Figure 25 
Concentration-response curves for the relaxant effect of glibenclamide in the 
endothelium-intact (A) mesenteric artery rings (〇，n=6 for control; • , n=4 for 10 | iM 
methylene blue) and (B) aortic rings (〇，n=9 for control; •，n=4 for 3 | iM 
indomethacin). Indomethacin was added to the bath 20 min prior to application of 
phenylephrine. Data are means 士 s.e. mean of n experiments. 
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3.1.6. Effect ofglibenclamide on high K"-induced arterial contraction 
Removal of the "endothelium only partially reduced the glibenclamide-
induced relaxation, indicating that other mechanisms are likely responsible for the 
endothelium-independent relaxation. It is possible that glibenclamide may have a 
direct relaxant action on smooth muscle through interfering with Ca^^ influx. To study 
this possibility, the effect of glibenclamide was examined on Ca^^ influx-mediated 
contraction. The trace in Fig. 26A shows that, in a 60 mM K+-contracted rat 
mesenteric artery, glibenclamide reduced the sustained contraction in a concentration-
dependent manner. The I C 5 0 values were 99.5 士 16.1 ^iM (n=6 for mesenteric arteries) 
and 137.7 士 21.3 ^iM (n=5 for aortic rings, Fig. 26B). Glibenclamide induced a full 
relaxation in both arteries (Fig. 26B), but it was slightly more effective in mesenteric 
arteries than in aortic rings. 
In another set of experiments, the effect of glibenclamide was examined on 
graded contractile response to increasing extracellular K+ concentration in the rat 
mesenteric arteries with endothelium. The traces in Fig. 27 show that the amplitude of 
tension development corresponded with graded increase ofK+ concentration from 10 
mM to 60 mM. When the tissue was exposed to glibenclamide (100 ^iM) for 30 min, 
the KCl-induced contraction was decreased (Fig. 27B). Figure 28 shows the 
concentration-response curves for various K+-induced contraction in the absence 
(Maximum tension: 4.92 士 0.4 mN, n=5) and presence of glibenclamide (Maximum 
tension: 4.44 士 0.4 mN，n=5 for 30 ^iM; 3.95 士 0.1 mN, n=4 for 100 ^iM; 1.20 士 0.3 
mN, n=4 for 300 ^ M glibenclamide, P<0.05 compared with control). These data show 
that glibenclamide inhibited the high K+-evoked contractions in a noncompetitive 
manner. 
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Figure 26 
(A) The trace showing a concentration-dependent relaxation induced by glibenclamide 
in an endothelium-intact rat mesenteric artery contracted with 60 mM extracellular K+. 
(B) Concentration-response curves for the relaxation induced by glibenclamide in 
endothelium-intact arteries precontracted with 60 mM K+ (〇，n=6 for mesenteric 
arteries;參，n=5 for aortic rings). Results are means 士 s.e.mean from n experiments. 
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Traces are representative records showing the contractile response to K+ in the 
absence (A) and presence of 100 ^iM glibenclamide (B) in the endothelium-intact rat 
mesenteric arteries. The artery was exposed to glibenclamide for 30 min before 
repeating the second concentration-dependent response to high K+. Calibration bars 
apply to both traces. 
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Figure 28 
The effect of glibenclamide on the high K+-induced contrations in rat endothelium-
intact mesenteric arteries. Concentration-response curves for KC1 in the absence (〇， 
n=5) and presence of glibenclamide (•，30 ^iM, n=5; • , 100 |iM, n=4; •，300 ^iM, 
n=4). Tissues were exposed to glibenclamide for 30 min before repeating the second 
concentration-response curve for KC1. Data are means 土 s.e. mean of n experiments. 
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In addition, I also examined the possible inhibitory action of glibenclamide 
2+ + 
on contractions induced by CaCl2 (0.1-10 mM) in Ca -free, 60 mM K -containing 
Krebs solution in the endothelium-denuded arterial rings. The trace in Fig. 29A shows 
a control experiment with a rat mesenteric artery; CaCl2 (0.1-10 mM) reproducibly 
induced a concentration-dependent contraction in the high K+ solution. However, 
exposure of the arterial ring to 100 | iM glibenclamide for 20 min reduced the 
contractile response to CaCl2 (Fig. 29B). The concentration-dependent inhibition by 
glibenclamide on CaCl2-induced contraction was shown in Fig. 30 (in mesenteric 
arteries, Fig. 30A and in aortic rings, Fig. 30B). By comparing the effect of 
glibenclamide in both arteries, it appears the glibenclamide was more effective in 
inhibiting CaCl2-induced contraction in rat mesenteric arteries than in rat aorta. 
Glibenclamide at 300 [iM abolished contraction of mesenteric arteries but this 
concentration only partially inhibited the contraction of aorta in response to CaCl2 in a 
depolarising solution (Fig. 30, Table 6). In addition, a L-type voltage-gated Ca^^ 
channel blocker, nifedipine at 10 nM, markedly suppressed the aortic contraction 
induced by CaCl2 (Fig. 30B), implying that the CaCl2-induced contraction in the high 
K+ solution was mainly mediated through Ca〗+ influx via voltage-gated Ca】+ channels 
of depolarised cell membrane. Table 6 summarises the effect of glibenclamide at 
various concentrations on 10 mM CaCl2-induced contraction of both rat mesenteric 
arteries and aortic rings in the 60 mM K+ solution. The results were expressed as the 
ratio (%) of the second CaCl2 contraction over the first CaCl2 contraction. The first 
contraction served as control and the second contraction in the presence of drug 
served as an index for the effect of glibenclamide. 
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Traces showing the contractile response to CaCl2 in the absence (A) and presence of 100 
HM glibenclamide (B) in the endothelium-denuded mesenteric arteries. The tissues were 
incubated with glibenclamide in a Ca^^-free, 60 mM K+ solution for 20 min before 
addition of CaCl2 (0.1-10 mM). Calibration bars apply to both traces. 
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Figure 30 
The effect of glibenclamide on CaCl2-induced contraction in 60 mM K+ solution. The 
concentration-dependent contraction induced by Ca〗+ (CaCl2) in the endothelium-
denuded (A) mesenteric arteries (〇，n=9 for control; •，n = 4 for 30 ^iM 
glibenclamide; •，n=5 for 100 ^iM glibenclamide; _ , n=5 for 300 ^iM glibenclamide) 
(B) aortic rings (〇，n=6 for control; •，n=5 for 100 ^iM glibenclamide; •，n=5 for 
300 ^iM glibenclamide; •，n=5 for 10 nM nifedipine) in a Ca^^-free, 60 mM K+ 
solution. The result is expressed as a percentage of the contraction induced by 10 mM 
CaCl2 in the first concentration-response curve. Data are means 士 s.e. mean of n 
experiments. 
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Table 6 Effect of glibenclamide on CaCl2-induced contraction 
Mesenteric artery Aorta 
Glibenclamide (uM) ^ C i { ^ n C2/C1(%) n 
0 127.2i7.6 9 125.0 i l8 .3 6 
10 133.7士13.3 5 ----- --
30 85.1 ±7 .4 * 4 143.9i29.2 5 
100 66.4±4.7* 5 125.1±29.5 5 
300 7.0士4.6 * 5 80.3 士14.4* 5 
The 0/0 contractile values induced by 10 mM CaCl2 [(second contraction, C2 / first 
contraction, Ci) x 100%] in control and in the presence of glibenclamide (10-300 [iM) 
or of nifedipine (10 nM) in rat endothelium-denuded mesenteric artery rings and aortic 
rings. Asterisks indicate a significant difference from the control value (P<0.05). 
Results are means 士 s.e. mean of n experiments. 
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3.1.7, Effect of glibenclamide on protein kinase C-mediated 
contraction 
In order to test the possibility that glibenclamide also relaxes the 
phenylephrine-preconstricted arteries probably through Ca^^-independent pathways, 
phorbol 12,13-diacetate (PDA), a protein kinase C activator, was used to elicit a 
sustained contraction in the absence of extracellular Ca】+. As shown in Fig. 31A, PDA 
at 1 | iM produced a slowly-developing tension in the absence of extracellular Ca】+ 
(zero Ca2+ plus 0.5 mM Na2-EGTA) and the maximum tension was 7.4 土 0.8 mN 
(n=10). Fig. 31A shows that the cumulative application of glibenclamide caused 
relaxation of the rat arteries preconstricted by PDA with an I C 5 0 values of 145.2 士 
11.6 ^iM (Emax: 81.4 土 4.7o/o, n=10) in rat mesenteric arteries and 363.2 土 32.4 ^iM 
(Emax： 87.7 土 7.5%, n=5) in rat aortic rings (Fig. 31B). Again, glibenclamide was more 
effective against PDA-induced contraction in mesenteric arteries than in aorta. 
Besides, staurosporine, a protein kinase C inhibitor, at 30 nM completely reversed 
contraction induced by 1 | iM PDA in a Ca^^-free solution and also by 0.3 ^iM 
phenylephrine in normal Krebs solution (n=4, data not shown). 
3.1.8, Effect of glibenclamide on prostaglandin F20rinduced 
contraction 
Since glibenclamide was suggested to act as a competitive antagonist of 
vasoconstricting prostanoids such as 9,11-dideoxy-l la,9a-epoxymethano-
prostaglandin F2a (U46619), an attempt was therefore made to compare the 
effectiveness of glibenclamide in relaxing arteries preconstricted by four different 
stimulants, 30 nM U46619, 1 ^iM phenylephrine, 60 mM K+ and 1 ^iM PDA. Once a 
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Figure 31 
(A) The representative trace showing a concentration-dependent relaxation induced by 
glibenclamide in a mesenteric artery ring pre-contracted with 1 ^iM PDA in a Ca^^-
free solution. (B) Concentration-response curves for the relaxation induced by 
glibenclamide in endothelium-denuded arteries precontracted by 1 ^iM PDA (〇，n=10 
for mesenteric arteries; •，n=5 for aorta). Curves were drawn by connecting adjacent 
data points. Results are means 士 s.e. mean from n experiments. 
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sustained tone was established with 30 nM U46619 in an endothelium-intact rat 
mesenteric artery, glibenclamide was added cumulatively to induce a concentration-
dependent relaxation (Fig. 32A). The I C 5 0 value was 0.28 士 0.06 ^iM (n= 6 , Fig. 32B). 
In another group of experiments, pretreatment with 1 ^iM glibenclamide significantly 
suppressed the amplitude of U46619 (30 nM)-induced contraction (6.9 士 0.7 mN for 
control; 3.8 士 1.0 mN, n=3 in each case, P<0.05, Fig. 33). Figure 34 contains four 
concentration-response curves for the relaxant effect of glibenclamide in arteries 
preconstricted by four constrictors. The I C 5 0 values were 0.28 士 0.06 ^iM (n=6 for 
U46619), 4.4 土 1.1 ^iM (n=8 for phenylephrine), 99.5 士 16.1 ^iM (n=6 for high K+) 
and 145.2 士 11.6 ^iM (n=10 for PDA). The order ofpotency for glibenclamide to relax 
arteries contracted by four constrictors are U46619 > phenylephrine > high K+ > PDA 
(Fig. 34). These results indicate that glibenclamide is a general muscle relaxant 
although it may antagonise the effect of prostaglandin at receptor levels. 
3.2. Glipizide 
J.2.i. Relaxant response of glipizide 
The possible relaxant activity of glipizide, another sulfonylurea drug, was 
also examined on contractions induced by four different constrictors in the 
endothelium-intact rat mesenteric arteries. The trace in Fig. 35A shows that, in 30 nM 
U46619-contracted artery, glipizide reduced the sustained contraction in a 
concentration-dependent manner. Figure 35B shows the concentration-response 
curves for the relaxant effect of glipizide on the contraction induced by U46619 (30 
nM, n=5), PDA (1 ^iM, n=5), phenylephrine (1 ^iM, n=4) and 60 mM K+ (n=5). It can 
be seen that glipizide was most effective against the U46619-induced contraction and 
85 
- Glibenclamide (uM) 
A. 0.03 0 1 
r ^ ^ 0.3 
/ ^ ^ " ^ ^ i ,L 




1 0 0 - ^ p ^ ^ 
- 0 U46619 Q ^ ^ ^ 
I 8。： / 
X 6 0 - J 
I 4 0 - / 
容 2 0 : ^ ^ 
^<y^^-
I I iiiii| I I I iiiii| I I I iiiii| I I I i i i i i | — r m 
0.01 0.1 1 10 
Glibenclamide (^M) 
Figure 32 
(A) The trace showing a concentration-dependent relaxation induced by glibenclamide 
in the rat mesenteric artery pre-contracted with 30 nM U46619. (B) Concentration-
response curve for the relaxation induced by glibenclamide in endothelium-intact 
mesenteric arteries precontracted by 30 nM U46619 (〇，n=6). Curve was drawn by 
connecting adjacent data points. Results are means 士 s.e. mean from 6 experiments. 
86 
A 
• W y^oMA 
A I G!iK^ 
J VJ l L ^ ^ 
6 0 m M K + u4*6619 5min 
B . W C . ^ n 
/ ^ t 8: T ^ 
/ ^ 6-
/ cS - * 
\ S 4- 丁 
\ x ^ 1 2 : n ^ 
^ \ / o -
會 N ^ / , . . . - ^ ^ u oJJ L 
60mMK+ • • # / ^ 
Glib U46619 / • , 
Figure 33 
Traces are representative records for the antagonistic effect of glibenclamide on 
U46619 (30 nM)-induced contraction. Glibenclamide (1 ^iM) was applied after (A) 
and 20 min before (B) addition of U46619 (30 nM). Calibration bars apply to both 
traces. (C) The effect of glibenclamide on 30 nM U46619-induced contraction. 
Asterisk indicates a significant difference from control (P<0.05). Data are means 士 
s.e. mean of 3 experiments. 
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Figure 34 
Concentration-response curves for the relaxation induced by glibenclamide in 
endothelium-intact rat mesenteric arteries pre-contracted with four constrictors (〇，30 
nM U46619, n=6; •，1 ^iM phenylephrine, n=8; •，60 mM K+, n=6; _ , 1 ^iM PDA, 
n=10). Data are means 士 s.e. mean of n experiments. 
88 
1 Gl ip iz ide ( ^ M ) 
A. <^  
/ ^ " " " ^ " " " " " " * " " ^ V J 。 . 0 
J iL^ 
I l O m i n X s ^ 
U46619 
B. 
0 U46619 30nM 
_ 令 PDA 1 ^ iM 
1 0 0 - C r ^ r p 
_ ^3- Phe 1 ^ iM r T ^ 
§ 80 一 + 60 mM K+ / K / 
I • / T j/_M 
容 : ^ ^ ^ 
- " I I Miii|~~I I I iiiii|~~I I I iiiii|~~I I I iiiii|~~I I I imi| 
0.001 0.01 0.1 1 10 
Glipizide (mM) 
Figure 35 
(A) The trace showing a concentration-dependent relaxation induced by glipizide in 
an endothelium-intact rat mesenteric artery ring pre-contracted with 30 nM U46619. 
(B) Concentration-response curves for the relaxation induced by glipizide in 
endothelium-intact mesenteric arteries precontracted with four constrictors (〇，30 nM 
U46619, n=5;參’ 1 ^ M PDA, n=5; • , 1 ^ iM phenylephrine, n=4; _ , 60 mM K+，n=5). 
Data are means 士 s.e. mean of n experiments. 
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Table 7 The relaxant effect of glipizide 
Max. dose IC^JjoM) E ^ (%) n 
30nMU46619 0.1 mM 6.7士2.1 100士1.1 5 
1 ^ M PDA 3 m M 1797.5 ±2652.4 * 95.1 ±3.1 5 
1 ^iM Phe 3 m M 320.9±43.9 * 96.7±3.3 4 
60mMK+ 3 m M --— 50.0±15.7* 5 
The values of I C 5 0 and maximum relaxation (Emax) are presented for the relaxant 
response to glipizide (0.001-3 mM) in endothelium-intact rat mesenteric arteries 
precontracted with U46619, PDA, phenylephrine or high K+. Asterisks indicates a 
significant difference from values with 30 nM U46619. Results are means ± s.e. 
mean of n experiments. Glipizide was dissolved in DMSO. When glipizide was 
used at a concentration higher than 3 mM, precipitation occurred in the bath 
solution. Therefore, higher concentration of glipizide was not used against the high 
K+ response in the present study. 
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least effective against the high K+ response (Fig. 35B). The I C 5 0 values were 6.7 土 2.1 
^iM for U46619, 1797.5 土 2652.4 ^iM for PDA and 320.9 士 43.9 ^ M for 
phenylephrine. Glipizide at 3 mM only reduced by approximately 50% the high K+-
induced contraction. The order of potency for the relaxant effect of glipizide on 
contractions induced by various constrictors was: U46619 > phenylephrine > PDA > 
high K+. The results are summarised in Table 7. This order of potency with glipizide 
is the same as that with glibenclamide (Fig. 34). 
3.3. Tolbutamide 
i.5.i. Contractile response to tolbutamide 
It was thought that another sulfonylurea drug, tolbutamide should have a similar 
inhibitory effect on arterial muscle tension since its chemical structure is similar to 
glibenclamide and glipizide (Fig. 1). It is surprising to observe that in arteries 
precontracted by phenylephrine (1 ^iM, 4.0 土 0.4 mN, n=4, Fig. 36A) or by 60 mM K+ 
(5.5 土 0.6 mN, n=4, Fig. 36B), tolbutamide (0.1-5 mM) caused a further increase of 
muscle tension in endothelium-intact mesenteric arteries (185.3 土 31.9o/o increase, n=4 
in arteries with phenylephrine and 21.3 士 3.8o/o increase, n=4 in arteries with 60 mM 
K+, Fig. 36B). This suggests that tolbutamide may have a direct vasoconstricting 
effect. Indeed, tolbutamide (1-5 mM) evoked a sustained contraction of rat mesenteric 
artery (Fig. 37A). Figure 37B shows the concentration-response curves for the 
contractile response to tolbutamide in both arteries. Tolbutamide at 5 mM caused a 
sustained tension of 4.5 土 0.4 mN (n=8) in mesenteric arteries and 3.0 土 0.5 mN (n=6) 
in aortic rings. The contractile effect of tolbutamide was significantly attenuated upon 
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Figure 36 
Traces are representative records showing the contractile response to tolbutamide 
(0.1-5 mM) on (A) 1 ^iM phenylephrine- or (B) 60 mM K+- contracted endothelium-
intact rat mesenteric artery. 
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Figure 37 
(A) The trace showing a concentration-dependent contraction induced by tolbutamide 
in rat endothelium-intact mesenteric artery. (B) Concentration-response curves for the 
tolbutamide-induced contraction in the rat endothelium-intact arteries (〇，n=8 for 
mesenteric arteries;參，n=6 for aortic rings). Tension was expressed as mN. Data are 
means 士 s.e. mean of n experiments. 
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at 5 mM produced significantly less contraction of 2.3 士 0.7 mN (n=7, P<0.05 
compared with that with endothelium, Fig. 38). 
3,3,2, Effects of endothelium-derived factors 
There may be several possibilities that tolbutamide could contract blood 
vessels. For example, tolbutamide may release vasoconstricting factors such as 
endothelins and prostaglandin to induce muscle contraction, since tolbutamide-
induced contraction was attenuated in endothelium-removed arteries (Fig. 38). To i 
examine this possible mechanism, I first tested the effect of endothelin I receptor 
antagonist, BQ610, on the tolbutamide-induced contraction. Figure 39 shows that 
BQ610 at 200 nM reversed the sustained contraction induced by 10 nM endothelin I 
(83.8 士 7.4o/o reversal, n=3, Fig. 39A & C) but this concentration of BQ610 was 
without an effect on the tolbultamide-induced contraction observed in three separate 
experiments (Fig. 39B & C). This finding can rule out the involvement of endothelial 
endothelin I in the contractile response to tolbutamide. 
In order to examine whether the presence of endothelium or basal nitric 
oxide may have underestimated the contractile action of tolbutamide, L-NNA was 
tested on tolbutamide-induced contraction in endothelium-intact rat mesenteric 
arteries. Figure 40 shows that 10 ^iM L-NNA caused further increase (274.6 士 36.5%， 
n=3) in muscle tension of the phenylephrine-contracted arteries (Fig. 40A & C) while 
100 ^iM L-NNA has no effect on the tolbutamide-contracted arteries (n=3, Fig. 40B & 
C). In addition, tolbutamide (0.1-5 mM) increased the basal tone but L-NNA (10-100 
|iM) did not, indicating that tolbutamide may not act as an inhibitor of nitric oxide 
synthase. 
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Figure 38 
Concentration-response curves for the contractile response to tolbutamide in rat 
mesenteric arteries (〇，n=8 with endothelium; # , n=7 without endothelium). Tension 
was expressed as mN. Data are means 士 s.e. mean ofn experiments. 
95 
BQ610(nM) 
A . 100 蚕 
f \ 200 7 
X ^ L 
\ lOmin 




D. V""*^ “ ^ 
_ r ^ 
^ r ^ BQ610 
^ J 5 200 nM 
-V^^^ ‘ i 
0.1 0.3 1 2 
r^ l |^ _______ 
Tolbutamide (mM) 5 min 
C' n n=3 n=3 
100-
^ o 8 0 -
C H -
a s 60-
C/5 ⑩ — -^ % 40-
^ C3 - * 
巴 20- ^ 
‘ , \ 々c/ - " 々 c / 
Figure 39 
(A) Marked reversal by BQ610 (200 nM) of endothelin I (10 nM)-induced 
contraction. (B) Lack of effect ofBQ610 (200 nM) on contraction induced by 5 mM 
tolbutamide. (C) Effect of BQ610 on endothelin I- or tolbutamide-induced 
contraction. This series of experiments was performed with endothelium-intact rat 
mesenteric arteries. Asterisk indicates a significant different from control {P<0.05). 
Data are means 士 s.e. mean of n experiments. 
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(A) A further contraction induced by N°-nitro-L-arginine (L-NNA, 10 ^iM) in a 
phenylephrine (1 jj,M)-contracted mesenteric artery with endothelium. (B) Lack of 
effect of 100 ^iM L-NNA on the contraction induced by 5 mM tolbutamide. (C) The 
effect of L-NNA (10 or 100 ^iM) on phenylephrine- and tolbutamide-induced 
contraction. Asterisk indicates a significant difference from control (P<0.05). Data are 
means ± s.e. mean of 3 experiments. 
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5.5.5. Effects of inhibitors of Ca�+ influx on tolbutamide-induced 
contraction 
In order to investigate whether the extracellular Ca】+ influx may account for 
the tolbutamide-induced response, the effect of extracellular Ca】+ was examined on 
contraction induced by tolbutamide in endothelium-intact mesenteric arteries. Figure 
41 shows that tolbutamide concentration-dependently induced a sustained contraction 
in normal Krebs solution containing 2.5 mM Ca】+, while removal of extracellular Ca】+ 
abolished the contractile response to tolbutamide (n=3), suggesting that extracellular 
Ca2+ is seemingly required for the tolbutamide-induced contraction. Figure 42 shows 
that neither nifedipine (30 nM, n=7), a voltage-dependent Ca^^ channel blocker, nor 
/ ^ i 
cadmium chloride (Cd, 300 ^M, n=7), a non-selective Ca channel blocker, affected 
the tolbutamide-induced contraction (Fig. 42C), while these two agents reversed the 
60 mM K+-induced increase of muscle tone by about 90% (Fig. 42A & B). In 
addition, higher concentration of cadmium chloride (500 ^M) or nifedipine (1 ^iM) 
had no effect no tolbutamide (5 mM)-induced contraction (n=3 in each case). Na】-
EGTA at 3 mM did not alter the tolbutamide-induced contraction (Fig. 42C). 
Besides, nickel sulphate, a presumed inhibitor of Na+.Ca】+ exchanger or of 
non-selective cation channels, partially reversed the sustained contraction induced by 
3 ^iM phenylephrine (n=3, Fig. 43A) and by 60 mM K+ (n=3, Fig. 43B), but it failed 
to affect the tolbutamide-induced contraction at a concentration range of30 to 300 |aM 
(Fig. 43B), while pretreatment with nickel (10 ^iM) for 30 min reduced the amplitude 
of tolbutamide-induced tension by approximately 90% (5.0 士 1.9 mN, n=4 for control 
and 0.4 土 0.1 mN n=4 for pretreatment ofnickel, P<0.05, Fig. 43D). 
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Figure 41 
Effect of extracellular CaCl2 on the tolbutamide-induced contraction. Concentration-
response curves for the tolbutamide-induced contraction in normal Krebs-Henseleit 
solution with 2.5 mM Ca】+ (〇，n=8) and in a Ca^^-free solution (•，n=3) in rat 
endothelium-intact mesenteric arteries. Tension was expressed as mN. Data are means 
士 s.e. mean of n experiments. 
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Figure 42 
Marked reversal by cadmium chloride (Cd, 300 p,M, A) or by nifedipine (30 nM, B) of 
60 mM K+-contracted mesenteric arteries with endothelium. (C) Lack of effect of 
cadmium chloride (Cd, 500 ^iM), nifedipine (1 ^iM) or N^-EGTA (3 mM) on 
contraction induced by 5 mM tolbutamide. (D) Effect of cadmium chloride or 
nifedipine on 60 mM K+- or tolbutamide-induced contraction. Asterisks indicates a 
significant difference from control (P<0.05). Data are means 士 s.e. mean of n 
experiments. 
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Figure 43 
Partial relaxation induced by nickel sulphate (300 ^M) of 3 ^iM phenylephrine (A)-
and 60 mM K+ (B)-contracted mesenteric artery with endothelium. (C) Lack of effect 
of nickel sulphate (30-300 |iM) on contraction induced by tolbutamide. (D) Effect of 
nickel sulphate on phenylephrine-, high K+- or tolbutamide-induced contractile 
response or pretreatment with 10 ^iM nickel on the tolbutamide-induced contraction. 
Asterisks indicates a significant difference from control (P<0.05). Data are means 士 
s.e. mean of n experiments. 
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Thapsigargin (10-30 nM), an inhibitor of endoplasmic reticulum Ca^^ 
ATPase, was without effect on the tolbutamide-induced contraction (n=3, Fig. 44B) 
while thapsigargin at 10 nM completely relaxed the phenylephrine-contracted arteries 
(n=4, Fig. 44A). However, pretreatment with thapsigargin (10 nM) for 30 min prior to 
addition of tolbutamide (5 mM) significantly reduced the sustained contraction 
induced by tolbutamide (amplitude of contraction: 5.3 土 2.1 mN, n=3 and 0.6 土 0.1 
mN, n=3, in the absence and presence of thapsigargin, Fig. 44C). 
3.3.4, Effects of forskolin，sodium nitroprusside, staurosporine on 
tolbutamide-induced contraction 
Inhibition of cyclic AMP- or cyclic GMP-dependent mechanism, and 
activation of protein kinase C would also lead to muscle contraction. In this series of 
experiments, the effects of cyclic neucleotide-generating agents or of protein kinase C 
inhibitor were examined on tolbutamide-induced contraction in rat mesenteric arteries. 
Figure 45 shows that the generator of cyclic GMP, SNP at 300 nM reversed the 
contraction induced by 9,11-dideoxy-l la,9a-epoxymethanoprostaglandin F2a 
(U46619, n=3, Fig. 45A), by 60 mM K+ (n=3, Fig. 45B) or by phenylephrine (Phe, 
n=3, Fig. 45C). In contrast, SNP at a much higher concentration (3 ^iM) did not 
suppress the tolbutamide-induced contraction (n=7, Fig. 45D & E). Similarly, 
forskolin (0.1-1 p,M), an adenylate cyclase activator, failed to affect the tolbutamide-
induced contraction (n=3, Fig. 46B & C) while forskolin at 100 nM completely 
relaxed the phenylephrine-contracted arteries (n=4, Fig. 46A & C). 
In vascular smooth muscle cell, activation of protein kinase C could cause 
vasoconstriction. To study whether tolbutamide-induced contraction results from its 
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Figure 44 
(A) Complete reversal by thapsigargin (10 nM) of 3 ^iM phenylephrine-induced 
contraction. (B) Lack of effect of thapsigargin (10-30 nM) on the contraction induced 
by 5 mM tolbutamide. (C) Pretreatment with thapsigargin (10 nM) reduced the 
amplitude of 5 mM tolbutamide-induced contraction. These experiments were 
performed with endothelium-intact rat mesenteric arteries. Asterisk indicates a 
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Figure 45 
Marked reversal by sodium nitroprusside (SNP, 300 nM) of 20 nM U46619 (A) and 
60 mM K+ (B) and 1 ^ M phenylephrine (C)-contracted mesenteric arteries with 
endothelium. (D) Lack of effect of SNP (3 ^iM) on the contraction induced by 5 mM 
tolbutamide. (E) Effect of SNP on U46619-, high K+-，phenylephrine- or tolbutamide-
mduced contraction. Asterisks indicates a significant difference from control 
(P<0.05). Data are means 士 s.e. mean o f« experiments. 
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Figure 46 
(A) Complete reversal by forskolin (0.1 _ of 3 ^iM phenylephrine-induced 
contraction ofan endothelium-intact mesenteric artery. (B) Lack of effect of forskolin 
(0.1-1 _ on the contraction induced by tolbutamide (5 mM). (C) Effect offorskolin 
on phenylephrine- or tolbutamide-induced contraction. Asterisk indicates a significant 
difference from control (P<0.05). Data are means 士 s.e. mean ofn experiments. 
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activation of protein kinase C in vascular smooth muscle, staurosporine, an inhibitor 
of protein kinase C was examined. Staurosporine (30 nM) had no effect on the 
tolbutamide-induced contraction (n=7, Fig. 47B & C), but it caused over 90% 
relaxation of the PDA-contracted arterial tissues in a Ca^^-free Krebs solution (n=4, 
Fig. 47A). Therefore, the involvement of inhibition of cyclic neucleotide production 
or ofprotein kinase C activation can be discounted. 
Table 8 summarises the results concerning the possible effects of various 
agents on the contractile response to 5 mM tolbutamide in rat isolated mesenteric 
arteries with endothelium. 
3.3,5. Effect of neural factors 
In order to test whether tolbutamide could act on sympathetic nerves 
supplying blood vessels to release vasoconstricting transmitters, the effects ofvarious 
blockers were examined on the tolbutamide-induced contractile response. Firstly, 
prazosin (1 ^iM), an ai-adrenoceptor antagonist, was found to be ineffective against 
the tolbutamide-induced contraction (Fig. 48B & C)，while prazosin at a smaller 
concentration of 300 nM completely reversed the phenylephrine-induced contraction 
(Fig. 48A & C). Secondly, pretreatment for 20 min with guanethidine (10 ^iM), an 
adrenergic neurone blocker, did not alter the contraction induced by 5 mM 
tolbutamide (Fig. 49A & C). Finally, pretreatment for 60 min with 6-
hydroxydropamine hydrobromide (6-OHDA), a chemical toxin, had no effect on the 
tolbutamide-induced contraction (Fig. 49B & C). Table 9 summarises the effects of 
pretreatment with various agents on tolbutamide-induced contraction in rat 




j t / j f ^ lOmin Xs^^^ 
\H>*-^"^ ^ " * ^ * ^ * * * * ^ * > < " * ^ 
金 
PDA 
g Staurosporine ^ 
等 . i • 1 n=4 n=7 
yg-<*WA***MAM^ |QQ_ _=n:_^  
S ^ f 80-
§ H -
a ^ 60-^ c/3 o ;zi CD 二 -
- _ 榮 ^ 
lOmin ^ P n _ 
一 20-
i m ^ || !••^, 
• 晏 i 寒 / 
T。lb / / 
Figure 47 
(A) Complete reversal by staurosporine (30 nM) of 1 ^ iM PDA-induced contraction in 
a Ca2+-free bath solution. (B) Lack of effect of staurosporine (30 nM) on the 
contraction induced by tolbutamide (5 mM). This series of experiments was 
performed with endothelium-denuded rat mesenteric arteries. (C) Effect of 
staurosporine (30 nM) on PDA- or tolbutamide-induced contractile response. Asterisk 
indicates a significant difference from control {P<0.05). Data are means 士 s.e. mean of 
n experiments. 
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Table 8 Effects of various agents on tolbutamide-induced contraction 
Tolbutamide-induced Change in 
Agents tension (mN) tension (%) n 
5 ( ^ 5 b ^ i ) S n M lO iO^5 0.6 ±"5.g 3 
L-NNA100 ^ M 6.3±2.1 0.8±0.8 3 
Cd 500 \ iM 4.9士0.8 2.5士2.9 7 
Nifedipine 1 ^iM 4.9 士 0.8 2.4 士 2.8 7 
Thapsigargin 30 nM 5.3士2.1 4.6士4.6 3 
SNP 3 ^ M 4.3士1.0 0.9士1.7 7 
Staurosporine 30 nM 4.9 士 0.9 0.6 士 2.0 7 
Forskolin 1 ^ iM 4.2 士 0.8 1.3 ± 0.7 3 
Nickel 300 ^iM 5.0±1.9 2.0=tl.6 4 
Prazosin 1 ^ iM 4.5士1.0 0.7±1.3 6 
The change in tension (%) induced by various agents on 5 mM tolbutamide-induced 
contraction in rat mesenteric arteries. Results are means 士 s.e. mean of n experiments. 
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(A) Complete reversal by prazosin (300 nM) of 1 ^iM phenylephrine-induced 
contraction. (B) Lack of effect of prazosin (1 ^iM) on the contraction induced by 5 
mM tolbutamide. This series of experiments was performed with endothelium-intact 
rat mesenteric arteries. (C) Effect of prazosin on phenylephrine- or tolbutamide-
induced contractile response. Asterisk indicates a significant difference from control 
(P<0.05). Data are means 士 s.e. mean of n experiments. 
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Figure 49 
Lack of effect of pretreatment with guanethidine (10 ^iM, A) for 20 min or with 6-
hydroxydropamine hydrobromide (6-OHDA, 3 ^iM, B) for 60 min on 5 mM 
tolbutamide-induced contraction. (C) Effect of guanethidine and 6-OHDA on the 
contractile response induced by tolbutamide. Calibration bars apply to both traces in A 
and B. Tension was expressed as mN. Data are means 士 s.e. mean o f« experiments. 
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T a b l e 9 Effect of pretreatment with various agents on tolbutamide-induced 
contraction 
Agents Incubation time Tolbutamide-induced n 
(min) tension (mN) 
"control—… s T r O J 9 
10 nM Thapsigargin 30 0.6土0.1* 3 
10 ^ M Guanethidine 20 5.7士1.1 3 
3 ^iM 6-OHDA 60 4.9±0.5 4 
lO^iM Nickel 30 0.4±0.1 * 4 
1 ^iM Nifedipine 30 0.6 士 0.1 * 3 
The contractile force (mN) induced by various agents in rat mesenteric arteries with 
endothelium. Results are means 土 s.e. mean of n experiments. Asterisks indicate a 
significant difference from the control value (P<0.05). 
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3.4. Effect of glibenclamide on cGMP levels 
The inhibitory effect of L-NNA, L-NAME and methylene blue on 
glibenclamide-induced endothelium-dependent relaxation indicates that nitric oxide is 
likely involved. I next decided to determine whether glibenclamide-induced 
endothelium-dependent relaxation is associated with an increase of cyclic GMP level 
in arterial tissues. As shown in Fig. 50, glibenclamide at 100 ^iM induced about two-
fold increase in the tissue content of cyclic GMP in rat endothelium-intact aortic rings 
(5.67 士 0.85 pmol/mg protein, n=7, P<0.05 compared to the control value of 2.84 土 
0.15 pmol/mg protein, n=5). Pretreatment of tissues with L-NNA (100 ^iM) abolished 
the stimulatory effect of glibenclamide on cyclic GMP production (1.07 土 0.31 
pmol/mg protein, n=5). In addition, glibenclamide did not increase the tissue content 
of cyclic GMP in the endothelium-denuded rings (Fig. 50). Besides, L-NNA (100 
^M) also significantly decreased an increase of tissue cyclic GMP level induced by 10 
l iM Ach in endothelium-intact aorta induced (3.37 土 0.18 pmol/mg protein, n=6 for 
control and 0.65 士 0.22 pmol/mg protein, n=5 for L-NNA, P<0.05) 
3.5. Effect of glibenclamide on intracellular [Ca�+� in 
cultured endothelial cells 
In primarily cultured rat aortic endothelial cells, glibenclamide (1-100 ^iM) 
induced an increase of [Ca^^]i (Fig. 51A) and this effect was also observed in cultured 
2+ 
human umbilical vein endothelial cells (ECV-304) in which a larger increase of Ca 
signal was produced by glibenclamide (Fig. 51B). It is at present unknown whether 
this difference of response in two types of endothelial cells is due to a fact that 
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Effect of 100 ^iM glibenclamide on tissue cyclic GMP contents in endothelium-intact 
(first four columns) and -denuded (- Endo) aortic rings. (Phe, phenylephrine 0.2 |iM; 
Glib, glibenclamide 100 ^iM; L-NNA, N^-nitro-L-arginine 100 ^iM) The number of 
experiments is indicated at the bottom of each column. Asterisks indicates a 
significant difference between two group (P<0.05, one way ANOVA followed by 
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The [Ca ]i-elevating effect of glibenclamide (Glib) in (A) primarily cultured aortic 
endothelial cells and (B) cultured human umbilical vein endothelial cells (ECV-304). 
Glibenclamide (1-100 ^iM) increased [Ca^^]i (n=12 cells, A). Glibenclamide (30 ^iM)-
induced an increase in [Ca^^]i was reversed in the absence of extracellular Ca】+ (n=10 
cells, B). Ca2+ signal was measured by confocal microscopy. Data are means 士 s.e. 
mean from 10 to 12 cells. 
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endothelial cells in primary culture were found to be more difficult to form a 
confluence layer. Figure 51B shows that 30 ^iM glibenclamide-induced steady 
increase of [Ca〗+]】 returned to the basal level after removal of extracellular Ca】+ by 
additing 3 mM Na2-EGTA (a nominal Ca】+ free condition, 0.28 ^iM Ca】+ in this 
solution calculated by Eqcal software, Cambridge, UK) in cultured human umbilical 
vein endothelial cells. The stimulatory effect of 30 ^iM glibenclamide remained in a 
Ca2+-free solution, but this increase was transient (Fig. 52). Re-addition of 2.5 mM 
Ca2+ into the bathing solution, triggered a sustained rise of [Ca^^]i (Fig. 52A). In 
contrast, glibenclamide at 100 ^iM failed to elevate [Ca^^]i of rat thoracic aortic 
endothelial cells in primary culture in the absence of extracellular Ca!+ (n=4, pjg 
52B). 
3.6. Effect of glibenclamide on intracellular [Ca�+] in 
cultured aortic smooth muscle cells 
Because a large change in intracellular Ca?+ levels was difficult to achieve 
in rat aortic smooth muscle cells in primary culture, the rat thoracic aortic smooth 
muscle cell line (A7r5) was instead used in this study. A7r5 smooth muscle cells were 
excitable, which can spontaneously increase the intracellular Ca]+ levels under 
normal, non-stimulated condition. Figure 53A shows that 60 mM K+ after rapidly 
superfusing the cells, induced a biphasic increase of [Ca^^]i, a rapid phasic rise 
followed by a smaller in amplitude but more steady phase. This effect of high K+ can 
be washed out with Krebs-Henseleit solution (Fig. 53A and Fig. 54A) and repeatable 
(Fig. 53A). Glibenclamide at 30 ^iM reduced the high K+-induced rise of [Ca】+]( in 
A7r5 cells (n=3, Fig. 54B). The dihydropyridin antagonist of voltage-gated Ca】+ 
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(A) The [Ca ]j-elevating effect of 30 ^iM glibenclamide in cultured human umbilical 
vein endothelial cells: A small and transient-rise induced by glibenclamide in a Ca?+-
free solution, large and sustained-rise after addition of2.5 mM Ca:+ (n=10 cells). (B) 
In primarily cultured rat aortic endothelial cells, 100 ^iM glibenclamide did not 
increase [Ca^^]i in a Ca^^-free solution while addition of 2.5 mM Ca^^ increased 
[Ca2+]i in the presence of glibenclamide (n=4). Data are means 士 s.e. mean ofn cells 
or n experiments. 
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Typical traces showing [Ca ]i decreased by glibenclamide in aortic smooth muscle 
cells. (A) Stimulatory effect of 60 mM K+ on [Ca^^]j in cultured rat thoracic aortic 
smooth muscle cells (A7r5) was repeatable. (B) The inhibitory effect of 30 ^iM 




0 2.4- “ w 
• v^ ‘ 
1 ^ -
I! ; : i ^ l | 
0.8"| 1 1 1 1 ‘ 1 1 1 ‘ 
0 100 200 300 400 
Time (sec) 
B . 2.4] C . 2.8] 60mMK+ 
60mMK^  - ;7777:,.r 
0 _ 100 n M N i f 
•5 ^ T Glib30^M 2’4一 t[ Ca2+free 
� 1 I 一 2 k 
I :lK :UV 
— I — I — I — I — I I I I I — I — 1 — I — I I I I 
0 100 200 300 400 0 200 400 600 
Time (sec) Time (sec) 
Figure 54 
Effect ofglibenclamide (30 ^M, n=3, B) and nifedipine (100 nM, n=4, C) on 60 mM 
K+-induced increase of [Ca^^]i (control, n=3 in A) in rat thoracic aortic smooth muscle 
cells (A7r5). Data are means 士 s.e. mean of n experiments. 
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Figure 55 
The [Ca2+]i-elevating effect of tolbutamide in smooth muscle cell. (A) 60 mM K+- or 
5 mM-induced increase of [Ca^^]i in A7r5 cells. (B) 5 mM tolbutamide-induced 
increase of [Ca^^]i in A7r5 cells. (C) 5 mM tolbutamide-induced increase of [Ca^^]i in 
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Figure 56 
(A) The [Ca2+]i-elevating effect of 5 mM of tolbutamide in cultured thoracic aortic 
smooth muscle cell (A7r5). Tolbutamide-induced a little bit decrease of [Ca^^]i in a 
Ca=-free solution, and a large and sustained rise of [Ca^^]i after addition of 2.5 mM 
Ca + (n=4). (B) Nickel sulphate (1 mM, n=5) inhibited the 5 mM of tolbutamide-
induced increase of [Ca^^]j. Data are means 士 s.e. mean n experiments. 
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channels, nifedipine also completely reversed the increased level of smooth muscle 
Ca2+ in response to 60 mM extracellular K+ (n=4, Fig. 54C), indicating the high K+-
induced rise of [Ca^^]i was primarily mediated through Ca〗+ influx via voltage-
sensitive Ca2+ channels that had been opened by membrane depolarisation. 
3.7. Effect of tolbutamide on intracellular [Ca�+� in cultured 
aortic smooth muscle cells 
Figure 55A & B show that 5 mM tolbutamide increased [Ca^^]i of cultured 
rat thoracic aortic smooth muscle cells (A7r5). 60 mM extracellular K+ also elevated 
aortic [Ca^^]i (Fig. 55A). The average response of four different experiments in [Ca^^]i 
induced by 5 mM tolbutamide was presented in Fig. 55C. The stimulatory effect of 
tolbutamide was only happened in a 2.5 mM Ca^^-containing bathing solution. 
Tolbutamide had no effect in a Ca^^-free solution, but re-addition of2.5 mM Ca〗+ into 
the bathing solution, triggered a sustained rise of [Ca^^]i (n=4, Fig. 56A). And 
tolbutamide (5 mM) increased intracellular [Ca】+]，then nickel sulphate (1 mM) 
inhibited this increase (Fig. 56B). 
3.8. Effect of glibenclamide on proliferation of cultured 
endothelial cells 
Finally, the possible effect of glibenclamide on cell proliferation was 
investigated. Figure 57 shows that glibenclamide (1-100 ^iM) inhibited proliferation 
of cultured human umbilical vein endothelial cells in a concentration-dependent 
manner. Glibenclamide at a concentration greater than 10 ^iM started to suppress cell 
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Figure 57 
Effect of glibenclamide (1-100 ^iM) on human umbilical vein endothelial cell (ECV-
304, 5xlO^ cells) proliferation. Cells were treated with glibenclamide for one day. 
Vertical bars are means 士 s.e. mean of 8 experiments. Asterisks indicate a significant 
difference from the control value (P<0.05). 
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proliferation (n=8, P<0.05 compared with control, Fig. 57). Then, it was found that 
CaCl2 (0-5 mM) significantly inhibited endothelial cell proliferation (n=8, P<0.05 
compared with the control, Fig. 58). Figure 59 shows that in the presence of 1 mM L-
arginine, glibenclamide was still able to inhibit cell proliferation (n=6, i^<0.05) while 
pretreatment with 10 ^iM L-NAME did not significantly potentiate the inhibitory 
effect ofglibenclamide (n=6, Fig. 59). In addition, glibenclamide at 100 ^iM inhibited 
cell proliferation in the presence of 3 ^M methylene blue (n=6, Fig. 60). Methylene 
blue at 3 ^iM potentiated cell proliferation (Fig. 60). In addition, SNP at 10 ^iM 
inhibited cell proliferation (n=6, Fig. 60). Rp-8-cGMP (10 ^iM), a cGMP-dependent 
protein kinase inhibitor, partially antagonised the inhibitory effect of glibenclamide 
(100 ^iM) on cell proliferation (n=6, Fig. 61). Finally, 8-Br-cGMP, a cyclic GMP 
analogue, did not affect cell proliferation by itself, neither it affected the 
glibenclamide-induced inhibition (n=6, Fig. 61). 
3.9. Effect of glibenclamide on proliferation of cultured 
aortic smooth muscle cells 
To study the possible effect of glibenclamide on smooth muscle cell 
proliferation, the rat aortic smooth muscle cells (A7r5) was used. Figure 62 shows that 
glibenclamide inhibited smooth muscle cell proliferation at concentration higher than 
30 ^iM (n=6, P<0.05). Glibenclamide at 300 ^M reduced the rate of cell proliferation 
by about 3-fold. The protein kinase C activator, PDA promoted aortic smooth muscle 
cell proliferation and 100 |iM glibenclamide caused a small but significant inhibition 
of cell proliferation in the presence of PDA (n=6, Fig. 63). Besides, the oci-
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Figure 58 
Effect 0fCaCl2 (0-5 mM) on human umbilical vein endothelial cell (ECV-304, 5xlO^ 
cells) proliferation. Cells were treated with CaCl2 for one day. Zero Ca^^ was 
incubated with 0.5 mM Nai-EGTA. Vertical bars are means 士 s.e. mean of 8 
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Cell proliferation in human umbilical vein endothelial cells (ECV-304, 5xlO^ cells) in 
response to glibenclamide (100 ^iM), L-arginine (L-Arg, 1 mM) and N^-nitro-L-
arginine methyl ester (L-NAME, 10 ^iM). Cells were treated with drugs for one day. 
In experiments with L-arginine plus glibnelcmiade or L-NAME plus glibenclamide, 
L-arginine or L-NAME were added 30 min prior to addition of glibenclamide 
respectively. Asterisks indicate a significant difference (P<0.05). Data are means 士 
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Cell proliferation in human umbilical vein endothelial cells (ECV-304, 5xlO^ cells) in 
the presence of glibenclamide (100 ^iM), sodium nitroprusside (SNP, 10 ^iM) and 
methylene blue (MB, 3 ^iM). Cells were treated with drugs for one day. In 
experiments with methylene blue (3 fiM) plus glibenclamide (100 ^iM), methylene 
blue was added 30 min prior to addition of glibenclamide (100 ^iM). Data are means 士 
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Figure 61 
Cell proliferation in human umbilical vein endothelial cells (ECV-304, 5xlO^ cells) in 
the presence of glibenclamide (100 pM), Rp-8-pCPT-cGMPs triethylamine (Rp-8-
cGMP，10 |uM) and 8-Bromo-cGMP (8-Br-cGMP, 1 mM). Cells were treated with 
drugs for one day. In experiments with Rp-8-cGMP plus glibenclamide or 8-Br-cGMP 
plus glibenclamide, Rp-8-cGMP or 8-Br-cGMP were applied 30 min prior to addition 
ofglibenclamide. Asterisks indicate a significant difference {P<0.05). Data are means 
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Figure 62 
Concentration-dependent reduction of rat thoracic aortic smooth muscle cell 
proliferation (A7r5, 5xlO^ cells) induced by glibenclamide. Cells were incubated with 
glibenclamide for four days. Vertical bars are means 士 s.e. of 6 experiments. Asterisks 
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The effect of glibenclamide (100 |nM) on phorbol 12,13-diacetate (PDA, 0.5-1 ^iM)-
induced increase of rat thoracic aortic smooth muscle cell proliferation (A7r5, 5xlO^ 
cells). Cells were incubated with PDA in the presence or absence of glibenclamide for 
four days. Asterisks indicate a significant difference (P<0.05). Data are means 士 s.e. 
mean of 6 experiments. 
129 
proliferation, but the inhibitory effect of glibenclamide was decreased in the presence 
of phenylephrine (n=6, Fig. 64). Finally, it was found that nifedipine (0.3-1 ^M) 
significantly inhibited smooth muscle cell proliferation (n=6, P<0.05, Fig. 65). 
Therefore, it is possible that the antiproliferative action of glibenclamide might be 
related to its inhibitory effect on intracellular [Ca^^] in rat aortic smooth muscle cell as 
probably the case with nifedipine. 
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Figure 64 
The effect of glibenclamide (100 ^iM) on phenylephrine (Phe, 10 ^iM)-induced 
inhibition of rat thoracic aortic smooth muscle cell proliferation (A7r5, 5xlO^ cells). 
Cells were incubated with phenylephrine in the presence or absence of glibenclamide 
for four days. Asterisks indicate a significant difference (P<0.05). Data are means 士 
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Figure 65 
Concentration-dependent reduction of rat thoracic smooth muscle cell proliferation 
(A7r5, 5xlO^ cells) induced by nifedipine. Cells were incubated with nifedipine for 
four days. Asterisks indicate a significant difference from the control value 
(P<0.05). Data are means 士 s.e. mean of 6 experiments. 
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Chapter 4 Discussion 
4.1. Effect of glibenclamide 
Sulfonylurea drugs such as glibenclamide are well known for their blocking 
effects not only on the KAip channels of pancreatic P_cells (Sturgess et al., 1985) and 
also on vascular KAip channels and on relaxation induced by K+ channel activators or 
endogenous dilators in blood vessels (Standen et al., 1989，Nelson et al, 1990; 
Murphy and Brayden, 1995). Glibenclmiade was found to have no effect on Ca】+-
activated tC+ channels (Langton et aL, 1991), which are also important in the 
regulation of myogenic tone (Brayden and Nelson, 1992). The present results show 
that glibenclamide significantly attenuated the relaxation-induced by K+ channel 
openers, such as cromakalim and pinacidil, in both endothelium-intact and -denuded 
rat mesenteric artery in a concentration-dependent fashion. The concentration-
response curve for the relaxant effect of cromakalim or pinacidil was shifted to the 
right in the presence of glibenclamide (0.3-1 pM). However, a higher concentration of 
glibenclamide was required to antagonise the relaxant effect of pinacidil in 
endothelium-intact preparations, this indicates that the presence of intact endothelium 
may have partially inhibited the effects of K+ channel openers and thus reduced the 
sensitivity of glibenclamide to inhibit the activity of the KMP channels in the 
endothelium-intact arteries. 
On the other hand, glibenclamide at higher concentrations was found to be a 
potent inhibitor of thromboxane A2-induced contraction in mammalian arteries (Cocks 
et aL, 1990; Nielsen-Kudsk and Thirstmp, 1991; Zhang et aL, 1991). bi the canine 
coronary artery, glibenclamide (1-30 ^iM) was found to competitively inhibit the 
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contractile response to a thromboxane A2 analogue, U46619, whilst glibenclamide at 30 
^iM had no effect on either the E C 5 0 value or maximal contraction in response to 
endothelin I, noradrenaline or high K+ (Cocks et al., 1990). In contrast, glibenclamide 
could inhibit the high-K+-induced contraction in rabbit coronary arteries with I C 5 0 of 
114 ^iM O^ielsen-Kudsk and Thirstrup, 1991). In rat aorta, however, the noradrenaline-
induced contractile response was unaffected by glibenclamide (1-10 ^iM) (Buckingham 
et al., 1989). Therefore, glibenclamide may behave as a competitive antagonist of 
vasoconstricting prostanoids as originally suggested by Cocks et al. (1990). However, 
accumulating amount of evidence shows that gliblenclamide may not act solely as a 
competitive antagonist since glibenclamide is found to also inhibit the contractile 
response of some vascular tissues to a number of constrictors, such as phenylephrine, 
endothelin I，or high extracellular K+ (Huang and Chan, 1998; Stanke et al” 1998). In 
addition, glibenclamide was reported to suppress contractions of the rat uterus in 
response to oxytocin, acetylcholine and KC1 (Villar et al., 1986) and contractions in 
response to a number of different spasmogens in airway smooth muscle ONfeilsen-Kudsk 
and Thirstrup, 1993). These reports suggest that glibenclamide at high concentrations 
may be a general smooth muscle relaxant, and that its effect is unlikely to be confined to 
the contractions induced by vasoconstricting prostanoids as proposed by Cocks et al. 
(1990). These findings from recent reports strongly indicate that glibenclamide may 
have multiple sites of action in vascular tissues. It is apparent that the observed 
inhibitory effect of glibenclamide on muscle contractility is a property additional to its 
pharmacological action as a selective blocker of ATP-sensitive K+ channels. The 
expected consequence of inhibition of ATP-sensitive K+ channels would be 
depolarization of the cell membrane, activation of voltage-sensitive Ca】+ channels and 
an increase in vascular tone. Indeed, in the present work (with pinacidil), as in many 
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other earlier studies (Standen et al., 1989), the vascular relaxation induced by a K+ 
channel activator was antagonized by glibenclamide at a low concentration, bi fact, 
glibenclamide is one of the most effective blockers of ATP-sensitive K+ channels in 
vascular smooth muscle (Standen et al., 1989) and it inhibits levcromakalim-induced 
relaxation of rat aorta with a Kj of 365 nM (Challinor-Rogers et al., 1995). It is 
probable, therefore, that the vasorelaxant action of glibenclamide is mediated by a 
mechanism independent of the involvement of ATP-sensitive K+ channels. 
The results of the present investigation show that glibenclamide induced 
both endothelium-dependent and -independent relaxation in rat isolated aortic rings 
and mesenteric arteries. Removal of the endothelium partially, but significantly, 
attenuated the glibenclamide-induced vasorelaxation. I next examined the possible 
role of endothelim-derived vasoactive factors in the glibenclamide response. 
Pretreatment of the endothelium-intact preparations with N^-nitro-L-arginine methyl 
ester (L-NAME), N^-nitro-L-arginine (L-NNA) or methylene blue, which are 
inhibitors of the endothelial nitric oxide/cyclic GMP-induced vasorelaxation, 
significantly reduced the glibenclamide-induced relaxation to the same as with 
endothelium-denuded tissues. On one hand, exposure of arterial rings to L-arginine, 
the precursor of nitric oxide, enhanced the relaxant response to glibenclamide, and on 
the other hand, L-arginine partially but significantly, antagonized the effect of L-
NAME on glibenclamide-induced relaxation. In contrast, indomethacin, an inhibitor 
of endothelial prostacyclin formation, had no effect, indicating that the relaxing 
prostanoids are not involved. These findings clearly suggest that glibenclamide may 
act on the endothelium to release nitric oxide which primarily accounts for the 
endothelium-dependent relaxation. Once released from the endothelium, nitric oxide 
readily diffuses into the adjacent smooth muscle cells to stimulate guanylate cyclase 
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and subsequent cGMP production which produces a nitric oxide-mediated relaxation 
(Ignarro et aL, 1984; Lugnier and Komas, 1993; Stoclet, 1991; Woodman, 1995). The 
present results show that exposure of endothelium-intact aortic rings to glibenclamide 
for 20 min raised the tissue concentration of cGMP by approximately two folds, and 
this rise was abolished in the presence of the nitric oxide synthase inhibitor, L-NNA, 
or in the endothelium-denuded rings. It can be ruled out that the effects of L-NAME 
or L-NNA were non-specific since L-NAME inhibited the relaxation induced not only 
by glibenclamide but also by endothelium-dependent dilators, such as acetylcholine or 
A23187, while glibenclamide was ineffective against the relaxation induced by the 
endothelium-independent dilator, sodium nitroprusside. Besides, L-NNA also 
inhibited acetylcholine-induced increase in the cGMP content of the same 
preparations (Huang et al., 1999). Similarly, methylene blue but not L-NNA 
attenuated relaxation induced by sodium nitroprusside in the present study or by 
hydroxylamine, a suggested endogenous precursor of nitric oxide (Huang, 1998). 
These results are in favour of a significant role of endothelium/nitric oxide in the 
glibenclamide-induced relaxation of the rat blood vessels. 
In response to various stimuli, the intact endothelium also secretes other 
vasodilating agents such as a yet unidentified endothelium-derived hyperpolarizing 
factor (EDHF) (Feletou and Vanhoutte, 1988; Chen & Suzuki，1990; Chen et al., 1991). 
EDHF causes membrane hyperpolarization and subsequent relaxation of the vascular 
smooth muscle through activation ofK+ currents (Feletou and Vanhoutte, 1988; Chen 
and Suzuki, 1990; Chen et aL, 1991). Besides, activation ofCa^^-activated K+ channels 
may partly mediate relaxation induced by EDRF/NO or by NO donors (Archer et al., 
1994; Huang 1998). The present results do not indicate that glibenclamide relaxes 
arterial smooth muscle through activation ofother types ofK+ channels since its effect 
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was unaffected by charybdotoxin, apamin and 4-aminopyridine, blockers for large- and 
small-conductance Ca^^-activated K+ channels, and voltage-sensitive K+ channels, 
respectively. The glibenclamide-induced relaxation in rat aorta was slightly reversed by 
tetraethylammonium ions. 
My results contrast the earlier observation with canine middle cerebral 
arteries in which glibenclamide-induced relaxation was unaltered by methylene blue 
or in the endothelium-removed tissues (Zhang et al., 1991). Zhang et al. (1991) 
concluded that the endothelium did not contribute to the relaxant effects of 
glibenclamide. This discrepancy may be caused by the use of different arteries from 
two species. It is at present not very clear how glibenclamide would stimulate release 
of nitric oxide from the endothelium in an isolated artery. However, I found that 
glibenclamide could induce a sustained increase of intracellular Ca:+ levels of cultured 
aortic endothelial cell line or in rat aortic endothelial cells in primary culture. It is, 
therefore, possible that glibenclamide acts on endothelium to raise [Ca^^]i, which then 
stimulates the activity of nitric oxide synthase, as a result, nitric oxide production and 
release is promoted. These results seem to be different from the recent observation by 
Volk et al. (1997), who found that nitric oxide can induce transient increase of Ca^^ in 
human umbilical cord vein endothelial cell (ECV-304). It is not known whether nitric 
oxide could further increase nitric oxide production in the later study of Volk et al. 
These results again show that nitric oxide is primarily involved in the glibenclamide-
mediated relaxation. 
The present study also shows that a larger portion of glibenclamide-induced 
rise of endothelial [Ca^^]i depends on the presence of extracellular Ca^+，this raises a 
possibility that glibenclamide induces Ca]+ influx probably through changing the cell 
membrane potential. In epithelial cells, glibenclamide was found to inhibit C1" outflow 
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currents or C1' secretion (Sheppard and Welsh, 1992; Huang and Wong, 1996). I f 
glibenclamide has the same blocking effect on vascular endothelial C1" channels, it 
would likely cause hyperpolarisation and thus increases the driving force for Ca^^ 
entry in non-excitable endothelial cells. This hypothesis needs to be substantiated with 
use of electrophysiological techniques. 
I have by far provided the first line of evidence demonstrating an 
endotheliumAiitric oxide-dependent component of the relaxant effect produced by 
glibenclamide. However, glibenclamide at higher concentrations can also induce a 
concentration-dependent endothelium-independent relaxation in both rat aorta and 
mesenteric arteries. The present results show that glibenclamide relaxed the high-K+-
preconstricted endothelium-denuded artery rings (Huang and Chan, 1998) or inhibited 
CaCl2-induced contraction in 60 mM K+-containing Krebs solution. This finding is 
consistent with the previous report with the rabbit aorta (Yoshitake et al., 1991). 
Glibenclamide was demonstrated to reduce intracellular Ca】+ levels and force without 
affecting the [Ca^^]i-force relationship (Yoshitake et al., 1991), implying that the 
relaxant action of glibenclamide in arterial tissues does not result from a reduced Ca^ + 
sensitivity of contractile proteins, but may involve the initial steps along the 
excitation-contraction pathway. The present study indicates that glibenclamide may 
interfere with Ca^^ influx through voltage-sensitive Ca^^ channels since glibenclamide 
reduced the increase of [Ca^^]i induced by 60 mM extracellular K+ in cultured aortic 
smooth muscle cells within a similar concentration range that relaxed the high K+-
contracted arteries. Nifedipine (100 nM), the L-type voltage-dependent Ca:+ channel 
blocker, completely reversed the effect ofhigh K+ on smooth muscle [Ca^+]. 
Apart from the stimulatory effect on plasma membrane Ca】+ channels 
through depolarisation, a high K+ condition would likely exert Ca〗+ channel-
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independent actions such as activation of protein kinase C (Low et al., 1994)，which 
can also cause muscle contraction even with normal resting [Ca^^]i (Rasmussen et al., 
1987). The present results show that glibenclamide could cause a concentration-
dependent reduction of sustained contractile response to the protein kinase C activator 
in the absence of extracellular Ca^^. This suggests that the protein kinase C-mediated 
steps in excitation-contraction coupling may also be the site of action for 
glibenclamide when it is used at higher concentrations. These findings indicate that 
glibenclamide-induced endothelium-independent vasorelaxation can be attributable to 
both inhibition of Ca〗+ influx through voltage-gated Ca^^ channels and suppression of 
protein kinase C-mediated contractile mechanisms. 
The reversal of the pinacidil-induced relaxation in endothelium-intact arteries 
was observed with 0.03 to 1 \ iM glibenclamide (the concentration for the half maximum 
reversal effect was 0.56 ^iM), while the inhibition of the phenylephrine-induced 
contraction was observed with 0.3 to 100 f iM glibenclamide (the concentration for the 
half maximum inhibition was 4.4 ^iM). The difference in concentration range between 
the two effects of glibenclamide would suggest that glibenclamide may act at two 
distinct sites. In endothelium-denuded rings of rat aorta, glibenclamide inhibited the 
specific binding of [^]P1075, an analogue of pinacidil, with a pKi of 6.4, a value which 
correlates well with the corresponding pD2 value of 7.0 calculated for the inhibition of 
P1075-evoked 86Rb+ efflux from rat aorta (Bray and Quast, 1992). However, with 
[^H]glibenclamide used as the radiolabel in membrane preparations from guinea pig 
ileum smooth muscle,j9KD values of 9.4 (high affmity component) and 7.1 (low affinity 
component) were obtained for glibenclamide (Zini et al, 1991). It appears that the 
glibenclamide binding site which inhibits the relaxant effect of cromakalim in guinea 
pig ileum may be related to the high-affinity glibenclamide receptors (Zini et al., 1991). 
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Nevertheless, it remains to be determined whether the relaxant effect ofglibenclamide is 
associated with the low-affinity binding site in rat mesenteric arteries. 
My results demonstrate that glibeclamide can induce both endothelium-
dependent and endothelium-independent relaxation. In order to further investigate the 
mechanisms involved in the relaxant response of glibenclamide on the endothelial cell 
or smooth muscle cell, I examined the effects of glibenclamide on proliferation of 
both endothelial cells and rat aortic smooth muscle cells. The present results obtained 
from proliferation experiments show that glibenclamide exerts an antiproliferative 
effect on both cultured endothelial cells and aortic smooth muscle cells in a 
concentration-dependent manner, but the effect is more profound on endothelial cells. 
Yang et aL (1994) described that exogenous nitric oxide donors inhibited proliferation 
of cultured vascular endothelial cells, but there has been no study to investigate 
whether endogenously synthesized nitric oxide may also affect the vascular 
endothelial cell proliferation. I demonstrated that nitric oxide released from 
endothelium was involved in glibenclamide-induced response. It is possible that nitric 
oxide in the presence of glibenclamide may inhibit proliferation of endothelial cells 
and this effect might be associated with glibenclamide-induced increase of 
intracellular [Ca^^] in endothelium. Therefore, I tried to examined the effects of nitric 
oxide-related agents, such as L-arginine, L-NAME, methylene blue and the exogenous 
nitric oxide donor on the endothelial cell proliferation. The nitric oxide donor sodium 
nitroprusside had an inhibitory effect on the endothelial cell proliferation. In contrast, 
the inhibitor ofnitr ic oxide synthase, L -NAME or soluble guanylate cyclase inhibitor, 
methylene blue slightly promoted proliferation of the endothelial cells. It seems that 
glibenclamide-induced inhibition of endothelial cell proliferation may be partially 
mediated by cyclic GMP-dependent mechanisms. Therefore, it further indicated that 
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glibenclamide induces a nitric oxide-mediated mechanism. However, both L-NAME 
and methylene blue slightly attenuated but not abolished the effect of glibenclamide, 
suggesting that other mechanisms are also present. 
On the other hand, I also measured the inhibitory effect of glibenclamide on 
proliferation of cultured rat aortic smooth muscle cells. In contrast, cell proliferation 
can be promoted by protein kinase C activator. It is reasonable to postulate that 
glibenclamide may also inhibit cell proliferation based on its acute relaxant effect on 
contractions mediated by phenylephrine or protein kinase C activators since either 
increased Ca】+ or activated protein kinase C-dependent pathway is knowingly 
involved in proliferation of smooth muscle cells (Kaplan-Albuquerque and Di Salvo, 
1998; Kataoka et aL, 1997; Rasmussen et aL, 1987; Watts et al., 1995). The present 
study shows that glibenclamide at higher concentrations inhibited proliferation of 
cultured aortic smooth muscle cells in the presence of phenylephrine or PDA. PDA 
alone increased cell proliferation. These data may further suggest an inhibitory effect 
of glibenclamide on the protein kinase C-mediated cellular response. Besides, 
nifedipine, a L-type Ca〗+ channel blocker, induced an antiproliferative effect in 
vascular smooth muscle cell in a concentration-dependent manner. There may be a 
link between glibenclamide-induced reduction of cell proliferation and glibenclamide-
induced decrease in intracellular [Ca^^]. There are a number of important therapeutic 
implications associated with the antiproliferative action of glibenclamide (Peuler et 
aL, 1996). Arterial smooth muscle cell proliferation is known to contribute 
importantly to development of atherosclerosis and may also contribute to hypertension 
(Sowers, 1992). Thus, it is possible that glibenclamide might have beneficial effects 
on the vascular system. 
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I also found that increased Ca】+ concentration in culture medium also 
inhibited proliferation of the endothelial cell in a concentration-related manner and 
glibenclamide triggered an increase in endothelial [Ca^^]. Therefore, it can not be 
ruled out that increased intracellular [Ca】+] may be partly involved in the inhibitory 
effect of glibenclamide on endothelial cell proliferation. 
Taken together, the present results demonstrate that glibenclamide exerts 
KATP channel-independent effect on the rat isolated aorta and mesenteric artery. It 
induces both endothelium-dependent and -independent relaxation. Nitric oxide but not 
other endothelium-derived factors is primarily responsible for the glibenclamide-
induced endothelium-dependent relaxation. Interference with Ca^^ influx through 
voltage-sensitive Ca^^ channels or with the protein kinase C-mediated contractile 
mechanism is likely involved in the endothelium-independent relaxation induced by 
glibenclamide at high concentrations. These data may also suggest that glibenclamide 
may have two sites of pharmacological actions, antagonism of the vasodilator effect to 
K+ channel activators (Standen et aL, 1989; Huang and Chan, 1998) and 
vasorelaxation (Huang and Chan, 1998). Since there is an overlap in the 
concentrations of glibenclamide that induce aforementioned two distinct vascular 
responses, it is possible that use of glibenclamide as a selective KMP channel blocker 
may have led to an underestimation of the role of KAip channels in control of smooth 
muscle contractility. It remains to be determined whether glibenclamide has a 
beneficial effect in the vascular system when it is clinically used in type II diabetic 
patients. 
142 
4.2. Effect of glipizide 
Similar to the results with glibenclamide, the results of the present study 
demonstrate that in the rat isolated mesenteric artery, vasorelaxant effect of glipizide 
is also KATP channel-independent. Glipizide and glibenclamide are structurally 
similar, their vascular action may be the same. Glipizide was found to inhibit KAip 
channels in vascular tissues (Loffler and Quast, 1997; Nielsen-Kudsk and Thirstrup, 
1993). Like glibenclamide, glipizide was the far more effective against contraction 
induced by a thromboxane mimetic, U46619, than other vasoconstrictors. The order of 
potency for the relaxant effects of glibenclamide or glipizide in arteries contracted 
with four constrictors are U46619 > phenylephrine > PDA > high K+. This indicates 
that glibenclamide and glipizide may also act antagonists of constricting prostaglandin 
receptors as previously described by Nielsen-Kudsk and Thirstmp (1993). The data 
are consistent with previous observation in rabbit coronary artery O^ielsen-Kudsk and 
Thirstrup, 1991). But the I C 5 0 value ( 2 2 2 土 83 ^M) of glipizide to reverse the 
contractile response to prostaglandin F2a is much higher than that ( I C 5 0 : 6 . 7 士 2 . 1 ^iM) 
obtained in my study with rat isolated mesenteric artery. It is suggesting to note that 
the potency for glipizide or glibenclamide to induce vasorelaxation is different 
between rat aorta and mesenteric arteries, they are being more effective relaxants in 
mesenteric arteries than in aorta although the exact reason is completely unknown. I 
also found that glipizide only reduced by approximately 50% the high K+-induced 
contraction while nifedipine completely abolished the high K+ response. These results 
indicate that only partial inhibition of nifedipine-sensitive Ca】+ channel is involved in 
the relaxation mediated by glipizide. In contrast, glibenclamide almost totally 
abolished the high K+-induced contractile response. Further electrophysiological 
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experiments are required to confirm a direct inhibitory action of glibenclamide or 
glipizide on voltage-dependent Ca〗+ channels in isolated single arterial smooth muscle 
fibers. 
Like glibenclamide shown above, glipizide also caused a concentration-
dependent relaxation of the rat endothelium-denuded mesenteric arteries 
preconstricted by the protein kinase C activator, PDA, in the absence of extracellular 
Ca2+. This suggests that the protein kinase C-mediated steps along excitation-
contraction pathway may be another site of action for glipizide. Taken together, 
inhibition of Ca^+ entry and inhibition of protein kinase C-dependent intracellular 
process mainly account for the glipizide-induced vasorelaxation in endothelium-
denuded blood vessels, and this effect is not associated with KAip channels. 
4.3. Effect of tolbutamide 
Tolbutamide belongs to the first generation of sulfonylurea drugs, while 
glibenclamide and glipizide belong to the second generation of sulfonylureas. They 
have different pharmacokinetic properties even though they are structurally related 
(Feldman, 1985). These three hypoglyceamic agents possess KAip channel-blocking 
activity with different effectiveness with tolbutamide being least potent. (Feldman, 
1985). Tolbutamide ( I C 5 0 : 351 ^M) blocks the vascular KAjp channel and also 
attenuates the vasodilator effects of the K+ channel opener, such as pinacidil and 
cromakalim (Quayle et aL，1995). Since glibenclamide and glipizide cause 
vasorelaxation in both rat aorta and mesenteric arteries, it would be expected that 
tolbutamide should have a similar action. In present study, however, I observed a 
surprising response to tolbutamide in both rat isolated blood vessels. Tolbutamide 
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within a concentration range between 0.1 and 5 mM can further increase, instead 
decrease, of muscle tension that had been developed by phenylephrine or by 60 mM 
extracellular K+ in the endothelium-intact rat mesenteric arteries. These results are 
contrast to the previous report with a rat pulmonary artery in which tolbutamide 
reduced hypoxia-induced vasoconstriction (Robertson et aL, 1992). Lee et aL (1988) 
reported that pretreatment of the femoral artery with tolbutamide in conscious dogs 
potentiated the contractile response to noradrenaline by 19% and to phenylephrine by 
8%. But, no further experiments were carried out to elucidate the possible 
mechanisms of enhancing effect of tolbutamide in this study. The potentiating effect 
of tolbutamide on phenylephrine-contracted arteries could be partly explained by its 
KATP channel-blocking activity i f these channels were activated by the elevated 
vascular tone in a submaximally contracted artery. Blockade of KAip channels would 
first depolarise the cell membrane and resultantly activates voltage-sensitive Ca】+ 
channel and Ca?+ influx, and finally leads to muscle contraction. However, this 
possibility can be eliminated because more potent KMP channel blockers, 
glibenclamide or glipizide, did not further contract the artery in the presence of 
phenylephrine neither affected the basal tension. Besides, it was completely unknown 
whether tolbutamide alone could have a direct stimulatory effect on contraction of 
arterial smooth muscle. 
The present study provides a new line of evidence showing that tolbutamide 
can evoke a sustained tension in both endothelium-intact and -denuded rat aorta and 
mesenteric arteries in a concentration-dependent manner even in the absence of a 
constrictor. The similar action of tolbutamide has never been reported before in any 
vascular preparations. There may be several explanations for the tolbutamide-induced 
contractile response. They include (1) the KAip channels are active under basal tone in 
145 
an unstimulated artery and inhibition of KAip channels by tolbutamide causes muscle 
contraction through increased Ca!+ 础皿；（2) tolbutamide may act on endothelial 
cells to liberate vasoconstricting agents such as endothelin and prostaglandin, which 
then mediate vasoconstriction; (3) tolbutamide may directly stimulate Ca】+ influx 
through either voltage-sensitive Ca】+ channels or non-selective cation channels; (4) 
tolbutamide may activate Ca^^-indpenedent contractile mechanisms such as protein 
kinase C-mediated pathway in smooth muscle; (5) tolbutamide may inhibit other 
second messenger systems, such as cAMP and cGMP, which are coupled to 
vasorelaxation; and (6) tolbutamide may depolarise sympathetic nerve terminals to 
release constricting transmitters such as noradrenaline. To my best knowledge, this is 
the first report demonstrating the constricting effect of tolbutamide in blood vessels. 
Therefore, different sets of experiments were designed in an attempt to examine 
aforementioned hypotheses. 
The present results do not indicate that the contractile response to 
tolbutamide is mediated through blockade of the KAip channels in arterial smooth 
muscle cells of both rat aorta and mesenteric arteries. Glibenclamide, a KATP channel 
blocker that is more selective and potent than tolbutamide (Feldman, 1985), did not 
cause further increase of muscle tension developed by phenylephrine, nor did 
glipizide. Besides, glibenclamide did not affect the basal tone at concentrations that 
significantly attenuated cromakalim- or pinacidil-induced relaxation. Neither did 
glibenclamide influence tolbutamide-induced contraction in the present study. It is 
therefore unlikely the KAip channel plays a role in the tolbutamide-induced 
contraction. In isolated rat mesenteric arteries, glibenclamide did not affect the resting 
membrane potential but abolished hyperpolarization induced by K+ channel activators 
or calcitonin gene-related peptide O^elson et al., 1990), indicating that the resting 
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KATP channel activity is very low. Thus, the effect of tolbutamide must be mediated 
via a KATP channel-independent mechanism. 
I f tolbutamide acts on the endothelial cells to release vasoconstricting 
factors, removal of the functional endothelium should inhibit or even abolish the 
tolbutamide-induced contraction. In fact, tolbutamide was still able to contract the 
arterial preparations without endothelium, but the amplitude of tolbutamide-induced 
contraction was smaller in endothelium-denuded than -intact arteries. This 
discrepancy is unlikely due to a partial damage made to vascular smooth muscle cells 
which may occur during endothelium denuation procedure, because the same 
concentration of phenylephrine always produced a greater tension in endothelium-
denuded than -intact arteries. It can also be discounted that the endothelium-derived 
relaxing component accounts partially for the reduced contractile response to 
tolbutamide in endothelium-removed tissues since L-NAME had no effect at 
concentrations that markedly attenuated acetylcholine-induced relaxation (Huang et 
al., 1999). It is at present unknown what may have caused this difference of 
contractile response to tolbutamide in arteries with and without endothelium. 
Endothelin I is a potent vasoconstricting peptide first found in the endothelium 
(Yanagisawa et aI., 1988) and endothelin I at nanomolar concentrations causes tonic 
contraction probably through interaction with endothelin A receptors with high 
affinity in blood vessels (Rubanyi, 1992). BQ610, an antagonist of endothelin A 
receptor (Verheyden et aL, 1994), at 200 nM completely reversed the endothelin I (30 
nM)-induced contraction, whilst this concentration of BQ610 failed to affect the 
tolbutamide-induced contraction, indicating that endothelial endothelin is not 
involved. Besides, indomethacin, an inhibitor of cyclooxygenase which is involved in 
biosynthesis of prostanoids in the endothelium (Altiere et al., 1986; Rubanyi, 1992; 
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Shirahase et aL, 1987)，had no effect against the tolbutamide-induced contraction, 
suggesting that neither constricting nor relaxing prostanoids play a part. Finally, 
tolbutamide does not seem to act on endothelium as an inhibitor of nitric oxide 
synthesis since the contractile response to tolbutamide was unaffected by L-NNA. L-
NNA, a known inhibitor of nitric oxide synthase, did not induced a sustained increase 
in muscle tension unlike tolbutamide. L-NAME or L-NNA occasionally 
(approximately 5%) induced a transient contractile effect which may be owing to 
variation in tissue preparations or in individual rats. 
The vasoconstriction of a blood vessel is normally triggered by increased 
cytosolic [Ca〗+]. There are two major sources that contribute to a rise of intracellular 
[Ca2+], extracellular Ca】+ influx through plasma membrane and Ca】+ release from 
internal stores. The level of intracellular [Ca】+] is closely associated with the 
^1 
amplitude of muscle contraction. It is generally believed that internal Ca release 
occurs transiently and is usually responsible for a transient or phasic contractile 
^1 
response, while a tonic increase in tension is normally maintained by Ca influx. 
Therefore, I would like to investigate whether the tolbutamide-induced contraction is 
1^ 
mediated through external Ca entry across the cell membrane of arterial smooth 
muscle. The present results demonstrate that the contractile response of rat mesenteric 
arteries to tolbutamide was completely abolished in Ca^^-free Krebs solution. This 
clearly points to an important role of extracellular Ca^^ in the tolbutamide response. 
This possibility was further supported by a fact that tolbutamide at 5 mM induced an 
^, 
increase of intracellular [Ca ] in rat aortic smooth muscle in primary culture and the 
increased [Ca】+] declined to the basal level when extracellular Ca:+ was removed from 
the perfusion solution. In addition, tolbutamide nerve elevated intracellular [Ca】+] in 
Ca2+-free Krebs solution. 
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It is possible that tolbutamide may directly activate Ca^^ channels. Nifedipine, 
the dihydropyridine antagonist of voltage-sensitive Ca】+ channels in excitable cells at 
a concentration 33 time's higher than that used to completely abolish the high K+_ 
induced contraction, or cadmium chloride, a non-selective Ca^^ channel blocker 
(Huang et al., 1998), had little effect on the sustained contraction induced by 
tolbutamide; however, i f the artery was pretreated with nifedipine for 30 minutes, the 
amplitude of tolbutamide-induced contraction was reduced by over 80%. This finding 
is very intriguing. It appears that tolbutamide could promote nifedipine-sensitive Ca^+ 
entry as a trigger for the sustained contraction which is then maintained by a constant 
increase of nifedipine-insensitive Ca】+ influx. I f this explanation is true, then it is 
2+ 
possible that tolbutamide maintains the elevated level of intracellular Ca through 
either stimulation Ca】+ influx via non-selective cation channels or inhibition of Ca】+ 
extrusion. Nickel, a presumed inhibitor of Na^-Ca^^ exchanger or of non-selective 
cation channel (Ahmed et cd., 1998; Blackburn and Highsmith, 1990; Yamamoto et 
al., 1995), was found to slightly inhibit the tolbutamide-induced contraction at 300 
p,M, and to markedly suppress tolbutamide-induced increase of intracellular [Ca^+]. 
On the other hand, preincubation of arteries with nickel profoundly attenuated the 
tolbutamide-induced contraction in the present study. These results imply that Ca^^ 
influx through non-selective pathways may be involved in the vascular response to 
tolbutamide. 
Besides, thapsigargin, an inhibitor of endoplasmic reticulum Ca^^-ATPase 
(Thastrup et al., 1987), was without an effect on the tolbutamide-induced contraction. 
In contrast, pretreatment of thapsigargin at the same concentration, significantly 
reduced muscle tension produced by tolbutamide. Thapsigargin was shown to deplete 
intracellular Ca^^ stores and stimulates store-operated Ca】+ entry in a variety of cells 
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including smooth muscle cells (Yamamoto et aL, 1995). It is unlikely that tolbutamide 
acts like thapsigargin to promote Ca^^ influx by blocking the activity of endoplasmic 
reticulum Ca^^-ATPase since thapsigargin alone did not induce contraction in normal 
Krebs solution in both aorta and mesenteric arteries of rats. It is therefore possible that 
the inhibitory effect of thapsigargin may be independent of inhibition of endoplasmic 
reticulum Ca^^-ATPase. It remains to be determined how pretreatment with 
thapsigargin suppresses the tolbutamide-induced contractile response in the rat 
arteries. 
Phenylephrine, when occupies arterial ai-adrenergic receptors, wi l l stimulate 
G-protein-coupled phospholipase C, which then catalyses hydrolysis of PIP2 with 
formation of two intermediate second messenger signals, inositol triphosphate (IP3) 
and diacylglycerol (Berridge, 1993). Activation of protein kinase C by endogenous 
diacylglycerol or exogenous phorbol esters causes a steady rise of tension in smooth 
muscle cells. It is worthwhile testing whether tolbutamide contracts arteries through 
activating protein kinase C. The tolbutamide-induced contraction was unaffected by 
staurosporine, an inhibitor of protein kinase C. In contrast, staurosporine reversed the 
contraction developed by phenylephrine in normal Krebs solution or by an active 
phorbol esters, PDA, in the absence of extracellular Ca】+, suggesting that tolbutamide 
may not stimulate protein kinase C as does PDA. 
In vascular smooth muscle, many endogenous agents relax blood vessels 
through stimulation of cyclic neucleotide-dependent kinase (Ignarro and Kadowitz, 
1985; Vegesna and Diamond, 1984). Inhibition of cAMP- or cGMP-dependent 
mechanisms may lead to muscle contraction. The present results show that neither 
forskolin, an activator of adenylate cyclase, nor sodium nitroprusside, a cyclic GMP-
elevator, affected the tolbutamide-induced contraction. However, it is yet to be 
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determined whether tolbutamide would reverse the relaxation induced by either 
forskolin or sodium nitroprusside. I f it does, detection of the tissue content of cGMP 
using radioimmunoassay should provide a useful information. 
Stimulation of sympathetic nerves supplying the blood vessels normally 
release constricting transmitters such as noradrenaline and ATP. These chemical 
signals act on respective receptors on the cell membrane to induce vasoconstriction. 
The results from the present investigation do not indicate an involvement of 
adrenergic stimulation in the tolbutamide-induced contraction. Firstly, prazosin, a 
potent antagonist of ai-adrenoceptors (Janis et al, 1987)，did not affect tolbutamide-
induced contraction while a lower concentration of prazosin fully reversed or 
abolished the phenylephrine-induced contraction. Secondly, pretreatment with 
guanethidine, an adrenergic neurone blocker fNeal, 1994)，had no effect on 
tolbutamide-induced contraction. Finally，pretreatment with 6-hydroxydopamine, a 
chemical toxin (Inversen et al,, 1975), was again without an effect against 
tolbutamide-induced contraction. These data suggest that tolbutamide may not 
depolarise sympathetic nerve terminals by blocking KAip channels and then promote 
Ca2+ influx to induce transmission. It is also clear that tolbutamide must not act as an 
oci-adrenoceptor agonist. 
Glibenclamide and tolbutamide induce relaxation of non-vascular smooth 
muscle such as guinea tracheal muscle ^sfielsen-Kudsk et aL, 1990; Nielsen-Kudsk 
and Thirstmp, 1993; Thirstrup et al., 1997). I also collected some data with guinea-pig 
airway smooth muscle in which both glibenclamide and tolbutamide relaxed 
acetylcholine-contracted tissues in a concentration-dependent manner Q)ersonal 
communication). It is apparent that tolbutamide has at least two separate modes of 
action in arterial smooth muscle and in tracheal smooth muscle. It is currently unclear 
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why these two types of smooth muscle cells display opposite effector responses to 
tolbutamide. 
4.4. Conclusion 
The present study aimed to examine the vascular response to the 
sulfonylurea drugs, such as glipizide, glibenclamide and tolbutamide, in rat isolated 
aorta and mesenteric arteries. I have provided several pieces of novel information 
regarding the KAip channel-independent action of these sulfonylurea drugs on the rat 
arteries (Fig. 66). It is concluded from the present results that (1) glibenclamide-
induced both endothelium-dependent and -independent relaxation, the former is 
mainly mediated by endothelial nitric oxide but not other endothelium-derived 
vasoactive factors, and the latter is jointly mediated through inhibition of Ca?+ influx 
and of protein kinase C-dependent mechanism; (2) glibenclamide and glipizide are 
most effective against contraction induced by U46619 than other constrictors; (3) the 
antiproliferative effect of glibenclamide may be caused by increased endothelial 
[Ca2+] and probably by nitric oxide as well; (4) tolbutamide-induced contraction 
mainly due to extracellular Ca】+ influx via either Ca^^ channel or non-selective cation 
channel. 
In view of widespread use of sulfonylurea drugs as selective blockers of 
KATP channels, the role of KAip channels may have been underestimated in 
endothelium-intact arteries in the case with glibenclamide (endothelium-dependent 
vasorelaxation) or may have been overestimated in both endothelium-intact and -
denuded arteries in the case with tolbutamide (extracellular Ca^^-depednent 
vasocontraction). Therefore, precaution should be taken when these compounds are 
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Figure 66 
The mechanisms involved in the glibenclamide-induced relaxant response in blood 
vessels, which are supported by the results of my study. (1) Glibenclamide increase 
endothelial [Ca】+], (2) glbienclamdie inhibit Ca】+ influx via voltage-dependent Ca^^ 
channel in arterial smooth muscle, and (3) glbienclamide interfere with protein kinase 
C-mediated contractile mechanisms. NOS: nitric oxide synthase; G: G protein; PIP2: 
phosphatidylinositol 4,5-bisphosphate; DG: diacylglycerol; PKC: protein kinase C; 
GC: guanylate cyclase; cGMP: cyclic guanosine monophosphate; PKG: cGMP-
dependent protein kinase. 
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employed as blockers of arterial KATP channels. In addition, type II diabetic patients 
tend to develop some cardiovascular disorders such as hypertension, it is still 
unknown whether chronib medication with glibenclamide can have a clinical benefit 
on the vascular system or whether clinical use of tolbutamide may have unwanted 
influence on normal vascular function. 
Even though the present study has elucidated some mechanisms underlying 
the vascular response to the three sulfonylurea drugs in the rat blood vessels, the exact 
mechanisms in particular for the tolbutamide-induced contraction is incompletely 
understood. Additional experiments are certainly needed to provide a better 
understanding of the vascular action of tolbutamide. 
Part of these new results with glibenclamide was published (Huang and 
Chan, 1998) or has been recently submitted for consideration of publication (Chan et 
al.’ 1999a). Other new data are currently being prepared for full manuscripts and wi l l 
be submitted later on (Chan et al., 1999b，and Chan et al., 1999c). 
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